CUMULATIVE SUPPLEMENT 9

JAN'94-SEP'94

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Cumulative Supplement 9

SEPTEMBER 1994

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

CUMULATIVE SUPPLEMENT 9

SEPTEMBER 1994

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 14th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List and the OTC Drug Product List are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. Deletions new to the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing overstruck print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 14th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 15th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ADRIA LABORATORIES DIV ERBAMONT INC (ADRIA)	PHARMACIA INC (PHARMACIA)
BANNER GELATIN PRODUCTS CORP (BANNER GELATIN)	BANNER PHARMACAPS INC (BANNER PHARMACAPS)
CLONMEL CHEMICALS CO LTD (CLONMEL)	CLONMEL HEALTHCARE LIMITED (CLONMEL)
DUPONT PHARMACEUTICALS (DUPONT)	DUPONT MERCK PHARMACEUTICALS CO (DUPONT MERCK)
GYNEX INC (GYNEX)	BTG PHARMACEUTICALS CORP SUB BIOTECHNOLOGY GENERAL CORP (BTG PHARMS)
KABI PHARMACIA INC (KABI)	PHARMACIA INC (PHARMACIA)
MALLINCKRODT SPECIALTY CHEMICALS CO (MALLINCKRODT)	MALLINCKRODT CHEMICAL INC (MALLINCKRODT)
NORTH AMERICAN CHEMICAL CORP (NORTH AM CHEM)	GOLDEN PHARMACEUTICALS INC (GOLDEN PHARM)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
PHARMACEUTICAL BASICS INC (PHARM BASICS)	ROSEMONT PHARMACEUTICAL CORPORATION (ROSEMONT PHARM)
RICHLYN LABORATORIES INC (RICHLYN)	GLOBAL PHARMACEUTICAL CORPORATION (GLOBAL PHARM)
SQUIBB DIAGNOSTICS (SQUIBB)	BRACCO DIAGNOSTICS INC (BRACCO)

1.4 NEW INDICATIONS FOR PREVIOUSLY APPROVED DRUG PRODUCTS

When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by the same firm, the application is either submitted as a supplement to the original NDA (if the clinical expertise for the review of the new indication resides in the same division that reviewed the original NDA), or as a "Type 6 NDA" and assigned a new NDA number (if the clinical expertise for the review of the new indication resides in another review division). When an application is submitted to FDA for a new indication for a drug product that duplicates a drug product (same active moiety, same salt, same formulation, or same combination) already approved or marketed in the United States by a different firm, the application is classified as "Type 6" and assigned a new NDA number.For administrative purposes, FDA has been listing all "Type 6 NDA's" in the *Approved Drug Products with Therapeutic Equivalence Evaluations*, (ADP), even when the application was submitted by the original NDA holder. However, FDA has determined that the practice of listing a separate "Type 6 NDA" number in the ADP when the applicant is the original NDA holder may cause confusion to the ADP reader.

Accordingly, to prevent confusion and to eliminate duplicity of data, the approval of an application for a new indication for a previously approved drug product submitted by the original NDA holder will no longer be listed in the ADP. Any exclusivity awarded for that approval will be shown in the Patent and Exclusivity Information Addendum under the original NDA number. However, approval of an application for a new indication submitted by an applicant other than the original NDA holder will be shown in the appropriate drug product list of the ADP. Any exclusivity awarded will be shown under the NDA number of the new applicant.

All approvals of "Type 6" applications submitted by the original NDA holder currently in the ADP are listed in the table below. For reference purposes, the original NDA number is listed next to the corresponding "Type 6 NDA Number". This data ("Type 6 NDA Number") will continue to be listed in the remaining Cumulative Supplements to the 14th Edition of the ADP; but it will not appear in the 15th Edition of the ADP.

TYPE 6 NDA NUMBER	ORIGINAL NDA NUMBER	ACTIVE INGREDIENT (TRADE NAME)	DOSAGE FORM (ROUTE)
17-117	16-020	AMANTADINE HCL (SYMMETREL)	CAPSULE (ORAL)
17-118	16-023	AMANTADINE HCL (SYMMETREL)	SYRUP (ORAL)
50-697	50-662	CLARITHROMYCIN (BIAXIN)	TABLET (ORAL)
19-576	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
19-648	19-084	KETOCONAZOLE (NIZORAL)	CREAM (TOPICAL)
18-064	18-063	NADOLOL (CORGARD)	TABLET (ORAL)
20-109	19-886	NAFARELIN ACETATE (SYNAREL)	SPRAY, METERED (NASAL)
20-223	19-057	TERAZOSIN HCL (HYTRIN)	TABLET (ORAL)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF SEPTEMBER 1994.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1993) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1993	MAR 1994	JUN 1994	SEP 1994
DRUG PRODUCTS LISTED	9140	9153	9079	
SINGLE SOURCE	2144 (23.5%)	2151 (23.5%)	2150 (23.7%)	
MULTISOURCE	6996 (76.5%)	7002 (76.5%)	6929 (76.3%)	
THERAPEUTICALLY EQUIVALENT	6292 (68.8%)	6306 (68.9%)	6290 (69.3%)	
NOT THERAPEUTICALLY EQUIVALENT	527 (5.8%)	513 (5.6%)	458 (5.0%)	
EXCEPTIONS[1]	177 (1.9%)	183 (2.0%)	181 (2.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	5	
NUMBER OF APPLICANTS	526	528	490	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	MEDIGESIC PLUS			
AB	US CHEM	**325MG;50MG;40MG**	**N89115 001**	**JAN 14, 1986**
	@	325MG;50MG;40MG	N89115 001	JAN 14, 1986

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

> DLT >	**CO-GESIC**			
> DLT > **AA**	CENT PHARMS	**500MG;5MG**	**N89360 001**	**MAR 02, 1988**
> DLT >				
> ADD >	@	500MG;5MG	N89360 001	MAR 02, 1988
> ADD >				

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE			
AT	BAUSCH AND LOMB	**2%;0.79%**	**N40063 001**	**FEB 25, 1994**
	BOROFAIR			
AT	PHARMAFAIR	**2%;0.79%**	**N88606 001**	**AUG 21, 1985**
	@	2%;0.79%	N88606 001	AUG 21, 1985
	DOMEBORO			
AT	MILES	**2%;0.79%**	**N84476 001**	
AT +		**2%;0.79%**	**N84476 001**	

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	ABBOTT	**10%**	**N73664 001**	**AUG 30, 1994**
AN		**20%**	**N74037 001**	**AUG 30, 1994**

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D			
+	BURROUGHS WELLCOME	8MG;60MG	N19806 001	MAR 25, 1994

ALBUTEROL SULFATE

SYRUP; ORAL

	ALBUTEROL SULFATE			
> ADD > **AA**	MOVA	**EQ 2MG BASE/5ML**	**N74302 001**	**SEP 30, 1994**
> ADD >				

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	WARNER CHILCOTT	**EQ 2MG BASE**	**N72817 001**	**JAN 09, 1990**
AB		**EQ 4MG BASE**	**N72818 001**	**JAN 09, 1990**
	@	EQ 2MG BASE	N72817 001	JAN 09, 1990
	@	EQ 4MG BASE	N72818 001	JAN 09, 1990

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	MYLAN	**0.25MG**	**N74215 001**	**JAN 27, 1994**
AB		**0.5MG**	**N74215 002**	**JAN 27, 1994**
AB		**1MG**	**N74215 003**	**JAN 27, 1994**
AB		**2MG**	**N74215 004**	**JAN 27, 1994**
AB	NOVOPHARM	**0.25MG**	**N74085 001**	**FEB 16, 1994**
AB		**0.5MG**	**N74085 002**	**FEB 16, 1994**
AB		**1MG**	**N74085 003**	**FEB 16, 1994**
AB	ZENITH LABS	**0.25MG**	**N74294 001**	**JUL 29, 1994**
AB		**0.5MG**	**N74294 002**	**JUL 29, 1994**

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	ZENITH LABS	1MG	N74294 003	JUL 29, 1994
AB		2MG	N74294 004	JUL 29, 1994

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN

AP	BEDFORD	EQ 50MG BASE/ML	N63313 001	APR 11, 1994
AP		EQ 250MG BASE/ML	N63315 001	APR 11, 1994
AP	ELKINS SINN	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
AP	+	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992
AP		EQ 250MG BASE/ML	N63275 001	MAY 18, 1992
AP	+	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992

AMIKIN

@	APOTHECON	EQ 50MG BASE/ML	N50495 001	
@		EQ 250MG BASE/ML	N50495 002	
AP	* BRISTOL	EQ 50MG BASE/ML	N50495 001	
AP		EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
AP	*	EQ 250MG BASE/ML	N50495 002	
AP		EQ 250MG BASE/ML	N62562 002	SEP 20, 1984
@		EQ 50MG BASE/ML	N62562 001	SEP 20, 1984
@		EQ 250MG BASE/ML	N62562 002	SEP 20, 1984

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

	ABBOTT	5%;25GM/100ML	N19565 001	DEC 17, 1986
@		5%;25GM/100ML	N19565 001	DEC 17, 1986

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AP	FUJISAWA	25MG/ML	N87886 001	AUG 30, 1983
@		25MG/ML	N87886 001	AUG 30, 1983
AP	KING PHARMS	25MG/ML	N86606 001	
AP	SMITHKLINE BEECHAM	25MG/ML	N86606 001	

TABLET; ORAL
AMINOPHYLLINE

AB	GLOBAL PHARMS	100MG	N84574 001	
AB		200MG	N84576 001	
BD	LANNETT	100MG	N84588 001	
BD		200MG	N84588 002	
@		100MG	N84588 001	
@		200MG	N84588 002	
BD	RICHLYN	100MG	N84574 001	
BD		200MG	N84576 001	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER

+	JACOBUS	4GM/PACKET	N74346 001	JUN 30, 1994

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

AB	LEMMON	10MG	N86610 001	
AB		25MG	N86859 001	
AB		50MG	N86857 001	
AB		75MG	N86860 001	
AB		100MG	N86854 001	
AB		150MG	N86853 001	
@		10MG	N86610 001	
@		25MG	N86859 001	
@		50MG	N86857 001	
@		75MG	N86860 001	
@		100MG	N86854 001	
@		150MG	N86853 001	

AMOXICILLIN

CAPSULE; ORAL

		AMOXICILLIN		
> ADD >	**AB**	BIOCHEMIE	**250MG**	**N64076 001**
> ADD >				SEP 30, 1994
> ADD >	**AB**		**500MG**	**N64076 002**
> ADD >				SEP 30, 1994
		POLYMOX		
	AB	APOTHECON	**250MG**	**N63099 001**
				MAR 20, 1992
	AB		**500MG**	**N63099 002**
				MAR 20, 1992
	AB	BRISTOL MYERS	**250MG**	**N63099 001**
				MAR 20, 1992
	AB		**500MG**	**N63099 002**
				MAR 20, 1992

POWDER FOR RECONSTITUTION; ORAL

		POLYMOX		
		@ APOTHECON	125MG/5ML	N61851 001
		@	125MG/5ML	N62323 001
		@	250MG/5ML	N61851 002
		@	250MG/5ML	N62323 002
	AB	BRISTOL	**125MG/5ML**	**N61851 001**
	AB		**125MG/5ML**	**N62323 001**
	AB		**250MG/5ML**	**N61851 002**
	AB		**250MG/5ML**	**N62323 002**

AMPHETAMINE SULFATE

TABLET; ORAL

		AMPHETAMINE SULFATE		
		LANNETT	5MG	**N83901 001**
				AUG 31, 1984
			10MG	**N83901 002**
				AUG 31, 1984
		@	5MG	N83901 001
				AUG 31, 1984
		@	10MG	N83901 002
				AUG 31, 1984

AMPHOTERICIN B

INJECTABLE; INJECTION

		AMPHOTERICIN B		
	AP	FUJISAWA	**50MG/VIAL**	**N62728 001**
				APR 13, 1987

AMPHOTERICIN B

INJECTABLE; INJECTION

		AMPHOTERICIN B		
		@ FUJISAWA	50MG/VIAL	N62728 001
				APR 13, 1987

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

		POLYCILLIN		
		@ APOTHECON	EQ 125MG BASE/5ML	N62297 001
		@	EQ 250MG BASE/5ML	N62297 002
	AB	BRISTOL	**EQ 125MG BASE/5ML**	**N62297 001**
	AB		**EQ 250MG BASE/5ML**	**N62297 002**

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

		M.V.C. 9+3		
	AP	FUJISAWA	**10MG/ML;0.006MG/ML;0.5 UGM/ML;**	
			1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;	
			0.4MG/ML;0.36MG/ML;0.3MG/ML;	
			330 UNITS/ML;1 IU/ML	**N18440 002**
				AUG 08, 1985
		@	10MG/ML;0.006MG/ML;0.5 UGM/ML;	
			1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;	
			0.4MG/ML;0.36MG/ML;0.3MG/ML;	
			330 UNITS/ML;1 IU/ML	N18440 002
				AUG 08, 1985

ATENOLOL

TABLET; ORAL

		ATENOLOL		
	AB	GENPHARM	**50MG**	**N74126 001**
				MAR 23, 1994
	AB		**100MG**	**N74126 002**
				MAR 23, 1994
	AB	INVAMED	**25MG**	**N74265 001**
				FEB 28, 1994
	AB		**50MG**	**N74265 002**
				FEB 28, 1994

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	INVAMED	100MG	N74265 003	FEB 28, 1994

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
LOFENE

AA	LANNETT	0.025MG;2.5MG	N85372 001	
@		0.025MG;2.5MG	N85372 001	

AZITHROMYCIN DIHYDRATE

>ADD< POWDER FOR RECONSTITUTION; ORAL
>ADD< ZITHROMAX
>ADD< + PFIZER — EQ 1GM BASE/PACKET — N50693 001 — SEP 28, 1994
>ADD<

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

AT	PHARMADERM	500 UNITS/GM	N62158 001	
@		500 UNITS/GM	N62158 001	
AT	PHARMAFAIR	500 UNITS/GM	N62453 001	MAR 28, 1984
@		500 UNITS/GM	N62453 001	MAR 28, 1984

BACLOFEN

TABLET; ORAL
BACLOFEN

AB	ROYCE LABS	10MG	N73092 001	JAN 28, 1994
AB		20MG	N73093 001	JAN 28, 1994

BENZYL BENZOATE

EMULSION; TOPICAL
BENZYL BENZOATE

+	LANNETT	50%	N84535 001	
@		50%	N84535 001	

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL
DIPROLENE

+	SCHERING	EQ 0.05% BASE	N19408 001	JAN 31, 1986
@		EQ 0.05% BASE	N19408 001	JAN 31, 1986

GEL; TOPICAL
DIPROLENE

+	SCHERING	EQ 0.05% BASE	N19408 002	NOV 22, 1991

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

>ADD< AB TARO PHARMS — EQ 0.05% BASE — N74272 001 — SEP 30, 1994
>ADD<

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

>ADD< AB TARO PHARMS — EQ 0.05% BASE — N74271 001 — SEP 15, 1994
>ADD<

BETAMETHASONE VALERATE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

B*	CLAY PARK	EQ 0.1% BASE	N71478 001	DEC 23, 1987
@		EQ 0.1% BASE	N71478 001	DEC 23, 1987

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

AA	LANNETT	5MG	N84702 001	
AA		10MG	N84712 001	

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

AA	LANNETT	25MG	N84074 001	
@		5MG	N84702 001	
@		10MG	N84712 001	
@		25MG	N84074 001	

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DX

AA	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML	N11694 007	MAR 29, 1984

BUDESONIDE

AEROSOL, METERED; NASAL
RHINOCORT

+	ASTRA	0.05MG/INH	N20233 001	FEB 14, 1994

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTALAN

	LANNETT	33.3MG/5ML	N85880 001	
@		33.3MG/5ML	N85880 001	

TABLET; ORAL
BUTISOL SODIUM

AA	WALLACE	100MG	N00793 005	
		100MG	N00793 005	

SODIUM BUTABARBITAL

AA	LANNETT	100MG	N85881 001	
@		100MG	N85881 001	
AA	ZENITH	30MG	N84040 001	
@	ZENITH LABS	30MG	N84040 001	

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

BR	G AND W LABS	100MG;2MG	N86557 001	OCT 04, 1983

WIGRAINE

BR	ORGANON	100MG;2MG	N86557 001	OCT 04, 1983

CALCIFEDIOL

CAPSULE; ORAL
CALDEROL

	ORGANON	0.02MG	N18312 001	
+		0.05MG	N18312 002	

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL
CALDEROL

	ORGANON	0.02MG	N18312 001	
+		0.05MG	N18312 002	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N20171 001	AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N20171 002	AUG 19, 1992

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N20171 003	AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 001	DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 002	DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 003	DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20183 004	DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER	18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N17512 004	

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	ABBOTT	18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 001	JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	ABBOTT	18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 002	JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	ABBOTT	18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 003	JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	ABBOTT	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 004	JUN 13, 1994

CARBACHOL

INJECTABLE; INJECTION

CARBACHOL

	@ PHARMAFAIR	0.01%	N70292 001	MAY 21, 1986

MIOSTAT

	* ALCON	0.01%	N16968 001	

SOLUTION; INTRAOCULAR

CARBACHOL

	@ PHARMAFAIR	0.01%	N70292 001	MAY 21, 1986

MIOSTAT

	+ ALCON	0.01%	N16968 001	

CARBAMAZEPINE

SUSPENSION; ORAL

TEGRETOL

	+ BASEL PHARMS	100MG/5ML	N18927 001	DEC 18, 1987
	* GEIGY	100MG/5ML	N18927 001	DEC 18, 1987

TABLET; ORAL

TEGRETOL

AB	+ BASEL PHARMS	200MG	N16608 001	
AB	* GEIGY	200MG	N16608 001	

TABLET, CHEWABLE; ORAL

TEGRETOL

AB	+ BASEL PHARMS	100MG	N18281 001	
AB	* GEIGY	100MG	N18281 001	

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	SCS	10MG;100MG	N74080 001	MAR 25, 1994
AB		25MG;100MG	N74080 002	MAR 25, 1994
AB		25MG;250MG	N74080 003	MAR 25, 1994

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR

	MERCK SHARP DOHME	25MG;100MG	N19856 002 DEC 24, 1992	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB	APOTHECON	EQ 500MG BASE	N62291 001	
AB	ZENITH LABS	EQ 500MG BASE	N62766 001 MAR 03, 1987	
	@	EQ 500MG BASE	N62766 001 MAR 03, 1987	

ULTRACEF

AB	BRISTOL	EQ 500MG BASE	N62291 001	

POWDER FOR RECONSTITUTION; ORAL
CEFADROXIL

AB	APOTHECON	EQ 125MG BASE/5ML	N62334 001	
AB		EQ 250MG BASE/5ML	N62334 002	
AB		EQ 500MG BASE/5ML	N62334 003	

ULTRACEF

AB	BRISTOL	EQ 125MG BASE/5ML	N62334 001	
AB		EQ 250MG BASE/5ML	N62334 002	
AB		EQ 500MG BASE/5ML	N62334 003	

TABLET; ORAL
CEFADROXIL

AB	ZENITH LABS	EQ 1GM BASE	N62774 001 APR 08, 1987	
	@	EQ 1GM BASE	N62774 001 APR 08, 1987	

ULTRACEF

AB	APOTHECON	EQ 1GM BASE	N62390 001 JUN 10, 1982	
AB	BRISTOL	EQ 1GM BASE	N62390 001 JUN 10, 1982	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	FUJISAWA	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	FUJISAWA	EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986	
AP		EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986	
AP		EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987	
	@	EQ 500MG BASE/VIAL	N62688 002 NOV 17, 1986	
	@	EQ 1GM BASE/VIAL	N62688 003 NOV 17, 1986	
	@	EQ 10GM BASE/VIAL	N62688 004 NOV 17, 1986	
	@	EQ 20GM BASE/VIAL	N62688 005 AUG 03, 1987	

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

	FUJISAWA	EQ 1GM BASE/VIAL	N63294 002 MAR 31, 1994	
		EQ 2GM BASE/VIAL	N63294 003 MAR 31, 1994	

CEFUROXIME AXETIL

POWDER FOR RECONSTITUTION; ORAL
CEFTIN

+	GLAXO	EQ 125MG BASE/5ML	N50672 001 JUN 30, 1994	

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
SEFFIN

AP	GLAXO	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983	
AP		EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983	
	+	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983	

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

	SEFFIN		
	@ GLAXO	EQ 1GM BASE/VIAL	N62435 001 NOV 15, 1983
	@	EQ 2GM BASE/VIAL	N62435 002 NOV 15, 1983
	@	EQ 10GM BASE/VIAL	N62435 003 NOV 15, 1983

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC

	CHLOROFAIR		
AT	PHARMAFAIR	**1%**	**N62439 001** **APR 21, 1983**
	@	1%	N62439 001 APR 21, 1983

SOLUTION/DROPS; OPHTHALMIC

	CHLOROFAIR		
AT	PHARMAFAIR	**0.5%**	**N62437 001** **APR 14, 1983**
	@	0.5%	N62437 001 APR 14, 1983

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	PERIDEX		
AT	+ PROCTER AND GAMBLE	**0.12%**	**N19028 001** AUG 13, 1986
	PERIOGARD		
AT	COLGATE PALMOLIVE	**0.12%**	**N73695 001** JAN 14, 1994

CHLORMERODRIN, HG-197

INJECTABLE; INJECTION

	CHLORMERODRIN HG 197		
	@ BRACCO DXS	0.6-1.4mCi/ML	N17269 001
	@ SQUIBB	0.6-1.4mCi/ML	N17269 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

	CHLORPHENIRAMINE MALEATE		
AA	ZENITH	**4MG**	**N80779 001**
	@ ZENITH LABS	4MG	N80779 001

CHLORTHALIDONE

TABLET; ORAL

	THALITONE		
	HORUS THERAP	15MG	N19574 001 DEC 20, 1988
	+	15MG	N19574 001 DEC 20, 1988

CHOLESTYRAMINE

TABLET; ORAL

	QUESTRAN		
	+ BRISTOL MYERS SQUIBB	EQ 1GM RESIN	N73403 001 APR 28, 1994

CIMETIDINE

TABLET; ORAL

	CIMETIDINE		
AB	ENDO LABS	**200MG**	**N74281 001** MAY 17, 1994
AB		**300MG**	**N74281 002** MAY 17, 1994
AB		**400MG**	**N74281 003** MAY 17, 1994
AB		**800MG**	**N74329 001** MAY 17, 1994
AB	MYLAN	**200MG**	**N74246 001** MAY 17, 1994
AB		**300MG**	**N74246 002** MAY 17, 1994
AB		**400MG**	**N74246 003** MAY 17, 1994
AB		**800MG**	**N74246 004** MAY 17, 1994
AB	NOVOPHARM	**200MG**	**N74151 001** MAY 17, 1994

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	NOVOPHARM	300MG	N74151 002	MAY 17, 1994
AB		400MG	N74151 003	MAY 17, 1994
AB		800MG	N74463 001	MAY 17, 1994
	TAGAMET			
AB	SMITHKLINE BEECHAM	200MG	N17920 002	
AB		300MG	N17920 003	
AB		400MG	N17920 004	DEC 14, 1983
AB +		800MG	N17920 005	APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL			
AP	ENDO LABS	EQ 300MG BASE/2ML	N74005 001	AUG 31, 1994
	TAGAMET			
AP +	SMITHKLINE BEECHAM	EQ 300MG BASE/2ML	N17939 002	

SOLUTION; ORAL

	CIMETIDINE HCL			
AA	BARRE	EQ 300MG BASE/5ML	N74176 001	JUN 01, 1994
	TAGAMET			
AA	SMITHKLINE BEECHAM	EQ 300MG BASE/5ML	N17924 001	

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001	JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
AP	BEDFORD	EQ 150MG BASE/ML	N63163 001	JUN 30, 1994

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE			
AP	DUPONT	EQ 150MG BASE/ML	N62908 001	FEB 01, 1989
@	DUPONT MERCK	EQ 150MG BASE/ML	N62908 001	FEB 01, 1989
AP	FUJISAWA	EQ 150MG BASE/ML	N62747 001	JUN 03, 1988
@		EQ 150MG BASE/ML	N62747 001	JUN 03, 1988

SOLUTION; TOPICAL

	CLEOCIN			
	UPJOHN	EQ 1% BASE	N50537 002	FEB 22, 1994

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB	COPLEY PHARM	0.05%	N74087 001	FEB 16, 1994
AB	NMC	0.05%	N74139 001	AUG 03, 1994
	TEMOVATE			
AB +	GLAXO	0.05%	N19322 001	DEC 27, 1985
AB +		0.05%	N20340 001	JUN 17, 1994

GEL; TOPICAL

	TEMOVATE			
+	GLAXO	0.05%	N20337 001	APR 29, 1994

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	COPLEY PHARM	0.05%	N74089 001	FEB 16, 1994
AB	NMC	0.05%	N74128 001	AUG 03, 1994
	TEMOVATE			
AB +	GLAXO	0.05%	N19323 001	DEC 27, 1985

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL
BASEL PHARMS 25MG N19906 001 DEC 29, 1989
50MG N19906 002 DEC 29, 1989
+ 75MG N19906 003 DEC 29, 1989
CIBA 25MG N19906 001 DEC 29, 1989
50MG N19906 002 DEC 29, 1989
+ 75MG N19906 003 DEC 29, 1989

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC W/ CODEINE
AA PENNEX **10MG/5ML;5MG/5ML; 6.25MG/5ML** **N88896 001** JAN 04, 1985
@ PENNEX PHARMS 10MG/5ML;5MG/5ML; 6.25MG/5ML N88896 001 JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ CODEINE
AA PENNEX **10MG/5ML;6.25MG/5ML** **N88875 001** DEC 17, 1984
@ PENNEX PHARMS 10MG/5ML;6.25MG/5ML N88875 001 DEC 17, 1984

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL
COLESTID
UPJOHN 1GM N20222 001 JUL 19, 1994

CORTISONE ACETATE

INJECTABLE; INJECTION
CORTISONE ACETATE
BP STERIS 25MG/ML N83147 003
BP 25MG/ML N85677 001
BP 50MG/ML N83147 004
BP 50MG/ML N85677 002
@ 25MG/ML N83147 003
@ 25MG/ML N85677 001
@ 50MG/ML N83147 004
@ 50MG/ML N85677 002
BP UPJOHN 25MG/ML N08126 002
@ 25MG/ML N08126 002
CORTONE
MERCK SHARP DOHME 25MG/ML N07110 002
+ 50MG/ML N07110 003
BP MSD 25MG/ML N07110 002
BP + 50MG/ML N07110 003

TABLET; ORAL
CORTISONE ACETATE
BP INWOOD 25MG N80731 001
@ INWOOD LABS 25MG N80731 001

CROMOLYN SODIUM

SOLUTION; INHALATION
CROMOLYN SODIUM
AN DEY **10MG/ML** **N74209 001** APR 26, 1994
INTAL
AN + FISONS **10MG/ML** **N18596 001** MAY 28, 1982

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL
RUBRATOPE-57
BRACCO DXS 0.5-1 uCi N16089 002
SQUIBB 0.5-1 uCi N16089 002

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL
RUBRATOPE-60
@ BRACCO DXS 0.5-1 uCi N16090 002

CYANOCOBALAMIN, CO-60

CAPSULE; ORAL
RUBRATOPE-60
@ SQUIBB — 0.5-1 uCi — N16090 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOGYL
AT * ALCON — 0.5% — N84109 001
\+ — 0.5% — N84109 001
PENTOLAIR
AT BAUSCH AND LOMB — 1% — N40075 001 APR 29, 1994
AT PHARMAFAIR — 0.5% — N88643 001 FEB 09, 1987
AT — 1% — N88150 001 FEB 25, 1983
@ — 0.5% — N88643 001 FEB 09, 1987
@ — 1% — N88150 001 FEB 25, 1983

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL
AA CHELSEA — 4MG — N86165 001
@ CHELSEA LABS — 4MG — N86165 001

CYSTEAMINE BITARTRATE

CAPSULE; ORAL
CYSTAGON
MYLAN — EQ 50MG BASE — N20392 001 AUG 15, 1994
\+ — EQ 150MG BASE — N20392 002 AUG 15, 1994

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE
\+ BULL D — 20MG/ML — N72945 001 FEB 28, 1994

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE
AP CETUS BEN VENUE — 1GM/VIAL — N74245 001 AUG 31, 1994
AP — 2GM/VIAL — N74245 002 AUG 31, 1994
CYTOSAR-U
AP \+ UPJOHN — 1GM/VIAL — N16793 003 DEC 21, 1987
AP \+ — 2GM/VIAL — N16793 004 DEC 21, 1987

DACTINOMYCIN

INJECTABLE; INJECTION
COSMEGEN
\+ MERCK SHARP DOHME — 0.5MG/VIAL — N50682 001
* MSD — 0.5MG/VIAL — N60467 001

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DESMOPRESSIN ACETATE
\+ RHONE POULENC RORER — 0.15MG/INH — N20355 001 MAR 07, 1994

DESONIDE

OINTMENT; TOPICAL
DESONIDE
AB TARO — 0.05% — N74254 001 AUG 03, 1994

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXASPORIN
AT BAUSCH AND LOMB — 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N64063 001 JUL 25, 1994

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

	DECADRON			
+	M3D	EQ 0.1MG PHOSPHATE/INH	N14242 001	
	DEXACORT			
+	MEDEVA	EQ 0.1MG PHOSPHATE/INH	N14242 001	

AEROSOL, METERED; INHALATION

	DECADRON			
+	M3D	EQ 0.1MG PHOSPHATE/INH	N13413 001	
	DEXACORT			
+	MEDEVA	EQ 0.1MG PHOSPHATE/INH	N13413 001	

> DLT > SOLUTION/DROPS; OPHTHALMIC

> DLT >	DEXAIR			
> DLT >	PHARMAFAIR	EQ 0.1% PHOSPHATE	N88433 001	
> DLT >			DEC 15, 1983	
> ADD >	@	EQ 0.1% PHOSPHATE	N88433 001	
> ADD >			DEC 15, 1983	

DEXTROAMPHETAMINE SULFATE

ELIXIR; ORAL

	DEXEDRINE			
	SMITHKLINE BEECHAM	5MG/5ML	N83902 001	
	@	5MG/5ML	N83902 001	

TABLET; ORAL

	DEXTROAMPHETAMINE SULFATE			
AA	LANNETT	**5MG**	**N83903 001**	
AA		**10MG**	**N83903 003**	
		15MG	**N85652 001**	
	@	5MG	N83903 001	
	@	10MG	N83903 003	
	@	15MG	N85652 001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE W/ DEXTROMETHORPHAN			
AA	PENNEX	**15MG/5ML;6.25MG/5ML**	**N88864 001**	
			JAN 04, 1985	
	@ PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001	
			JAN 04, 1985	

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	**50MG/ML**	**N16730 002**	

DEXTROTHYROXINE SODIUM

TABLET; ORAL

	CHOLOXIN			
	BOOTS	4MG	N12302 004	
+		6MG	N12302 006	
+		4MG	N12302 004	
@		6MG	N12302 006	

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

	CARDIOGRAFIN			
@	BRACCO DXS	85%	N11620 002	
@	SQUIBB	85%	N11620 002	

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

	SINOGRAFIN			
	BRACCO DXS	52.7%;26.8%	N11324 002	
	SQUIBB	52.7%;26.8%	N11324 002	

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	DYNAPEN			
AB	APOTHECON	**EQ 500MG BASE**	**N61454 003**	

DICUMAROL

TABLET; ORAL

	DICUMAROL			
	ABBOTT	25MG	N05545 003	
+		25MG	N05545 003	

DIENESTROL

CREAM; VAGINAL

	ESTRAGUARD			
AT	SOLVAY	0.01%	N84436 001	
@		0.01%	N84436 001	

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

> DLT >	TEPANIL			
> DLT > AA	3M	25MG	N11673 001	
> ADD > @		25MG	N11673 001	

DIETHYLSTILBESTROL

TABLET; ORAL

	DIETHYLSTILBESTROL			
BP	LILLY	1MG	N04041 004	
BP +		5MG	N04041 005	
		1MG	N04041 004	
+		5MG	N04041 005	
	STILBESTROL			
BP	TABLICAPS	1MG	N83002 001	
BP		5MG	N83006 001	
@		1MG	N83002 001	
@		5MG	N83006 001	

TABLET, DELAYED RELEASE; ORAL

	STILBESTROL			
BE	TABLICAPS	0.5MG	N83003 001	
BE		1MG	N83005 001	
BE		5MG	N83007 001	
@		0.5MG	N83003 001	
@		1MG	N83005 001	
@		5MG	N83007 001	
	STILBETIN			
BE	SQUIBB	0.5MG	N04056 012	
BE		1MG	N04056 013	
BE		5MG	N04056 014	
@		0.5MG	N04056 012	
@		1MG	N04056 013	
@		5MG	N04056 014	

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

	DILTIAZEM HCL			
AB	NOVOPHARM	30MG	N74084 001	FEB 25, 1994
AB		60MG	N74084 002	FEB 25, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL			
AA	LANNETT	25MG	N80868 001	
AA		50MG	N80868 002	
@		25MG	N80868 001	
@		50MG	N80868 002	
AA	ROXANE	50MG	N80635 001	
@		50MG	N80635 001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	DIPIVEFRIN HCL			
AT	ALCON	0.1%	N73636 001	JUN 30, 1994
	PROPINE			
AT +	ALLERGAN	0.1%	N18239 001	

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	EQ 400MG BASE/100ML	N20201 006	JUL 07, 1994
AP +	BAXTER	EQ 400MG BASE/100ML	N20255 005	OCT 19, 1993

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

	ZONALON			
+	GENDERM	5%	N20126 001	APR 01, 1994

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		ADRIAMYCIN PFS		
AP	*	**ADRIA**	**200MG/100ML**	**N50629 002 MAY 03, 1988**
AP			**200MG/100ML**	**N63165 002 JAN 30, 1991**
	+	PHARMACIA	200MG/100ML	N50629 002 MAY 03, 1988
			200MG/100ML	N63165 002 JAN 30, 1991
		DOXORUBICIN HCL		
> ADD >	**AP**	CETUS BEN VENUE	**200MG/100ML**	**N64097 001 SEP 13, 1994**
> ADD >				

ENFLURANE

LIQUID; INHALATION

	ENFLURANE		
AN	INHALON	**99.9%**	**N74396 001 JUL 29, 1994**

ERGOCALCIFEROL

CAPSULE; ORAL

	DELTALIN		
AA	LILLY	**50,000 IU**	**N80884 001**
	@	50,000 IU	N80884 001
	VITAMIN D		
AA	LANNETT	**50,000 IU**	**N80825 001**
	@	50,000 IU	N80825 001
AA	WEST WARD	**50,000 IU**	**N83102 001**
	@ WEST WARD PHARM	50,000 IU	N83102 001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC		
AB	PARKE DAVIS	**250MG**	**N62546 001 JUL 25, 1985**
	@	250MG	N62546 001 JUL 25, 1985

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN		
AT	BAUSCH AND LOMB	**0.5%**	**N64067 001 JUL 29, 1994**

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

		ERYTHROMYCIN		
AT		FOUGERA	**0.5%**	**N62447 001 SEP 26, 1983**
AT			**5MG/GM**	**N62447 001 SEP 26, 1983**
		ILOTYCIN		
AT	+	DISTA	**0.5%**	**N50368 001**
AT	*		**5MG/GM**	**N50368 001**

SOLUTION; TOPICAL

		ERYTHROMYCIN		
AT		BARRE	**2%**	**N62957 001 JUL 21, 1988**
	@		2%	N62957 001 JUL 21, 1988
AT		BAUSCH AND LOMB	**2%**	**N64039 001 JAN 27, 1994**
AT		PHARMAFAIR	**2%**	**N62616 001 JUL 25, 1985**
	@		2%	N62616 001 JUL 25, 1985

TABLET, COATED PARTICLES; ORAL

	PCE		
	ABBOTT	**333MG**	**N50611 001 SEP 09, 1986**
	+	333MG	N50611 001 SEP 09, 1986

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

		ERYTHROMYCIN ETHYLSUCCINATE		
AB		DISTA	**EQ 200MG BASE/5ML**	**N62177 001**
AB			**EQ 400MG BASE/5ML**	**N62177 002**
	@		EQ 200MG BASE/5ML	N62177 001
	@		EQ 400MG BASE/5ML	N62177 002
AB		PHARMAFAIR	**EQ 200MG BASE/5ML**	**N62559 001 MAR 15, 1985**
AB			**EQ 400MG BASE/5ML**	**N62558 001 MAR 15, 1985**
	@		EQ 200MG BASE/5ML	N62559 001 MAR 15, 1985
	@		EQ 400MG BASE/5ML	N62558 001 MAR 15, 1985

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL

	E.E.S. 400			
AB	+ ABBOTT	EQ 400MG BASE	N61905 001	
AB		EQ 400MG BASE	N61905 002	
			AUG 12, 1982	
AB	+	EQ 400MG BASE	N61905 002	
			AUG 12, 1982	
	@	EQ 400MG BASE	N61905 001	

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ERYPAR			
AB	PARKE DAVIS	EQ 250MG BASE	N62322 001	
	@ WARNER CHILCOTT	EQ 250MG BASE	N62322 001	
	ERYTHROMYCIN STEARATE			
AB	PUREPAC	EQ 250MG BASE	N61743 001	
	@ PUREPAC PHARM	EQ 250MG BASE	N61743 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	DELADUMONE			
AO	+ SQUIBB	4MG/ML;90MG/ML	N09545 001	
	@	4MG/ML;90MG/ML	N09545 001	
	TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE			
AO	STERIS	4MG/ML;90MG/ML	N85865 001	
	+	4MG/ML;90MG/ML	N85865 001	

ESTROGENS, ESTERIFIED

TABLET; ORAL

	ESTRATAB			
BS	SOLVAY	0.625MG	N83209 001	
BS	+	0.625MG	N83209 001	
BS		2.5MG	N83857 001	
BS	+	2.5MG	N83857 001	
	MENEST			
BS	+ SMITHKLINE BEECHAM	0.625MG	N84948 001	
BS		0.625MG	N84948 001	
BS	+	2.5MG	N84949 001	
BS		2.5MG	N84949 001	

ESTRONE

INJECTABLE; INJECTION

	ESTRONE			
BP	STERIS	2MG/ML	N83397 001	
	@	2MG/ML	N83397 001	

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

	MYAMBUTOL			
	LEDERLE	200MG	N16320 002	
		400MG	N16320 003	
	+	500MG	N16320 004	
	@	200MG	N16320 002	
	+	400MG	N16320 003	
	@	500MG	N16320 004	

ETHINAMATE

CAPSULE; ORAL

	VALMID			
	DISTA	500MG	N09750 001	
	@	500MG	N09750 001	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

	NORQUEST FE			
	+ SYNTEX	0.035MG;75MG;1MG	N18926 001	
			JUL 18, 1986	
	@	0.035MG;75MG;1MG	N18926 001	
			JUL 18, 1986	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
	WATSON	0.035MG,0.035MG;0.5MG,1MG	N71041 001	
			SEP 24, 1991	
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001	
			SEP 24, 1991	
	ORTHO-NOVUM 7/14-21			
AB	+ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004 001	
			APR 04, 1984	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	ORTHO-NOVUM 7/14-21				
	@ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004 001		
			APR 04, 1984		

TABLET; ORAL-28

	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
	WATSON	0.035MG,0.035MG;0.5MG,1MG	N71042 001		
			SEP 24, 1991		
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042 001		
			SEP 24, 1991		
	ORTHO-NOVUM 7/14-28				
AB	+ JOHNSON RW	0.035MG,0.035MG;0.5MG,1MG	N19004 002		
			APR 04, 1984		
	@	0.035MG,0.035MG;0.5MG,1MG	N19004 002		
			APR 04, 1984		

ETODOLAC

TABLET; ORAL

	LODINE		
+	WYETH AYERST	400MG	N18922 004
			JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE		
AP	GENSIA	**20MG/ML**	**N74284 001**
			FEB 10, 1994
	VEPESID		
AP	+ BRISTOL	**20MG/ML**	**N18768 001**
			NOV 10, 1983

FAMCICLOVIR

TABLET; ORAL

	FAMVIR		
+	SMITHKLINE BEECHAM	500MG	N20363 002
			JUN 29, 1994

FAMOTIDINE

INJECTABLE; INJECTION

	PEPCID IN PLASTIC CONTAINER		
+	MERCK	0.4MG/ML	N20249 001
			FEB 18, 1994

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

	PLENDIL			
+	ASTRA MERCK	2.5MG		N19834 004
			>_ADD_>	SEP 22, 1994
+		5MG	>_ADD_>	N19834 001
			>_ADD_>	JUL 25, 1991
+		10MG	>_ADD_>	N19834 002
			>_ADD_>	JUL 25, 1991
	MERCK	5MG	>_DLT_>	N19834 001
			>_DLT_>	JUL 25, 1991
		10MG	>_DLT_>	N19834 002
			>_DLT_>	JUL 25, 1991

FLUCONAZOLE

TABLET; ORAL

	DIFLUCAN		
+	PFIZER	50MG	N19949 001
			JAN 29, 1990
+		100MG	N19949 002
			JAN 29, 1990
		50MG	N19949 001
			JAN 29, 1990
		100MG	N19949 002
			JAN 29, 1990
		150MG	N20322 001
			JUN 30, 1994

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

	FLUDEOXYGLUCOSE F 18		
+	DOWNSTATE CLINCL	6.8-35.7mCi/ML	N20306 001
			AUG 19, 1994

FLUMAZENIL

INJECTABLE; INJECTION

		MAZICON		
	+	ROCHE	0.1MG/ML	N20073 001 DEC 20, 1991
		ROMAZICON		
	+	ROCHE	0.1MG/ML	N20073 001 DEC 20, 1991

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

		FLUOCINOLONE ACETONIDE		
> ADD >	AT	TARO PHARMS	0.025%	N40041 001 SEP 15, 1994
> ADD >				

SOLUTION; TOPICAL

		FLUOCINOLONE ACETONIDE		
	AT	PHARMAFAIR	0.01%	N88449 001 FEB 08, 1984
	@		0.01%	N88449 001 FEB 08, 1984

FLUOCINONIDE

CREAM; TOPICAL

		FLUOCINONIDE		
	B*	CLAY PARK	0.05%	N71790 001 JUL 13, 1988
	@		0.05%	N71790 001 JUL 13, 1988

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC

		FLUOR-OP		
> ADD >	AB	CIBA VISION	0.1%	N70185 001 FEB 27, 1986
> ADD >				
> DLT >	AB	IOLAB	0.1%	N70185 001 FEB 27, 1986
> DLT >				

FLUOROURACIL

INJECTABLE; INJECTION

		ADRUCIL		
AP	+	ADRIA	50MG/ML	N17959 001
AP			50MG/ML	N40023 001 OCT 18, 1991
AP	+	PHARMACIA	50MG/ML	N40023 001 OCT 18, 1991
	@		50MG/ML	N17959 001

FLURANDRENOLIDE

CREAM; TOPICAL

		CORDRAN SP		
	+	DISTA	0.025%	N12806 003
	+		0.05%	N12806 002
	+	LILLY	0.025%	N12806 003
	+		0.05%	N12806 002

LOTION; TOPICAL

		CORDRAN		
AT	+	DISTA	0.05%	N13790 001
AT	+	LILLY	0.05%	N13790 001

OINTMENT; TOPICAL

		CORDRAN		
	+	DISTA	0.025%	N12806 004
	+		0.05%	N12806 001
	+	LILLY	0.025%	N12806 004
	+		0.05%	N12806 001

TAPE; TOPICAL

		CORDRAN		
	+	DISTA	0.004MG/SQ CM	N16455 001
	+	LILLY	0.004MG/SQ CM	N16455 001

FLURBIPROFEN

TABLET; ORAL

		ANSAID		
AB		UPJOHN	50MG	N18766 002 OCT 31, 1988
AB	+		100MG	N18766 003 OCT 31, 1988
		FLURBIPROFEN		
AB		MYLAN	50MG	N74358 001 JUN 20, 1994

FLURBIPROFEN

TABLET; ORAL

	FLURBIPROFEN			
AB	MYLAN	100MG	N74358 002	JUN 20, 1994

FOLIC ACID

TABLET; ORAL

	FOLIC ACID			
AA	LANNETT	1MG	N80816 001	
	@	1MG	N80816 001	
AA	PUREPAC	1MG	N80784 001	
	@ PUREPAC PHARM	1MG	N80784 001	

FUROSEMIDE

INJECTABLE; INJECTION

	FUROSEMIDE			
AP	MARSAM	10MG/ML	N74017 001	JUN 30, 1994
AP	ORGANON	10MG/ML	N70017 001	DEC 15, 1986
	@	10MG/ML	N70017 001	DEC 15, 1986
AP	WARNER CHILCOTT	10MG/ML	N18420 001	FEB 26, 1982
	@	10MG/ML	N18420 001	FEB 26, 1982

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION

	GALLIUM CITRATE GA 67			
BS	DUPONT	2mCi/ML	N17478 001	
BS	DUPONT MERCK	2mCi/ML	N17478 001	

GEMFIBROZIL

TABLET; ORAL

	GEMFIBROZIL			
AB	PUREPAC PHARM	600MG	N74360 001	AUG 31, 1994

GENTAMICIN SULFATE

CREAM; TOPICAL

	GARAMYCIN			
AT	+ SCHERING	EQ 0.1% BASE	N60462 001	
AT	+	EQ 1MG BASE/GM	N60462 001	
	GENTAFAIR			
AT	PHARMAFAIR	EQ 1MG BASE/GM	N62458 001	SEP 01, 1983
	@	EQ 0.1% BASE	N62458 001	SEP 01, 1983
	GENTAMICIN			
AT	CLAY PARK	EQ 0.1% BASE	N62307 001	
AT		EQ 1MG BASE/GM	N62307 001	
	GENTAMICIN SULFATE			
AT	BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001	APR 29, 1994
AT	FOUGERA	EQ 0.1% BASE	N62531 001	JUL 05, 1984
AT		EQ 1MG BASE/GM	N62531 001	JUL 05, 1984
AT	NMC	EQ 0.1% BASE	N62471 001	SEP 27, 1983
AT		EQ 1MG BASE/GM	N62471 001	SEP 27, 1983
AT	THAMES	EQ 0.1% BASE	N62427 001	MAY 26, 1983
AT		EQ 1MG BASE/GM	N62427 001	MAY 26, 1983

INJECTABLE; INJECTION

	APOGEN			
AP	KING PHARMS	EQ 10MG BASE/ML	N62289 001	
AP		EQ 40MG BASE/ML	N62289 002	
AP	SMITHKLINE BEECHAM	EQ 10MG BASE/ML	N62289 001	
AP		EQ 40MG BASE/ML	N62289 002	
	GARAMYCIN			
AP	+ SCHERING	EQ 2MG BASE/ML	N50505 001	

INJECTABLE; INTRATHECAL

	GARAMYCIN		
	+ SCHERING	EQ 2MG BASE/ML	N50505 001

OINTMENT; OPHTHALMIC

	GARAMYCIN			
AT	+ SCHERING	EQ 0.3% BASE	N50425 001	
AT	+	EQ 3MG BASE/GM	N50425 001	
	GENTACIDIN			
AT	IOLAB	EQ 0.3% BASE	N62501 001	JUL 26, 1984

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

		GENTACIDIN		
AT		IOLAB	**EQ 3MG BASE/GM**	**N62501 001**
				JUL 26, 1984

OINTMENT; TOPICAL

		GARAMYCIN		
AT	+	SCHERING	**EQ 0.1% BASE**	**N60463 001**
AT	+		**EQ 1MG BASE/GM**	**N60463 001**
		GENTAFAIR		
AT		PHARMAFAIR	**EQ 0.1% BASE**	**N62444 001**
				MAY 26, 1983
	@		EQ 0.1% BASE	N62444 001
				MAY 26, 1983
		GENTAMICIN		
AT		CLAY PARK	**EQ 0.1% BASE**	**N62351 001**
				FEB 18, 1982
AT			**EQ 1MG BASE/GM**	**N62351 001**
				FEB 18, 1982
		GENTAMICIN SULFATE		
AT		BAUSCH AND LOMB	**EQ 0.1% BASE**	**N64054 001**
				APR 29, 1994
AT		FOUGERA	**EQ 0.1% BASE**	**N62533 001**
				OCT 05, 1984
AT			**EQ 1MG BASE/GM**	**N62533 001**
				OCT 05, 1984
AT		NMC	**EQ 0.1% BASE**	**N62496 001**
				MAR 14, 1984
AT			**EQ 1MG BASE/GM**	**N62496 001**
				MAR 14, 1984
AT		PHARMADERM	**EQ 0.1% BASE**	**N62534 001**
				OCT 10, 1984
AT			**EQ 1MG BASE/GM**	**N62534 001**
				OCT 10, 1984
AT		THAMES	**EQ 0.1% BASE**	**N62477 001**
				DEC 23, 1983
AT			**EQ 1MG BASE/GM**	**N62477 001**
				DEC 23, 1983

SOLUTION/DROPS; OPHTHALMIC

		GARAMYCIN		
AT	+	SCHERING	**EQ 0.3% BASE**	**N50039 002**
AT	+		**EQ 3MG BASE/ML**	**N50039 002**
		GENOPTIC		
AT		ALLERGAN	**EQ 0.3% BASE**	**N62452 001**
				OCT 10, 1984

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

		GENOPTIC		
AT		ALLERGAN	**EQ 3MG BASE/ML**	**N62452 001**
				OCT 10, 1984
		GENTACIDIN		
AT		IOLAB	**EQ 0.3% BASE**	**N62480 001**
				MAR 30, 1984
AT			**EQ 3MG BASE/ML**	**N62480 001**
				MAR 30, 1984
		GENTAFAIR		
	@	PHARMAFAIR	EQ 0.3% BASE	N62440 001
				MAY 03, 1983
		GENTAMICIN SULFATE		
AT		AKORN	**EQ 0.3% BASE**	**N62635 001**
				JAN 08, 1987
AT			**EQ 3MG BASE/ML**	**N62635 001**
				JAN 08, 1987
AT		BAUSCH AND LOMB	**EQ 0.3% BASE**	**N64048 001**
				MAY 11, 1994
AT		STERIS	**EQ 0.3% BASE**	**N62523 001**
				NOV 25, 1985
AT			**EQ 3MG BASE/ML**	**N62523 001**
				NOV 25, 1985

GLIPIZIDE

TABLET; ORAL

		GLIPIZIDE		
AB		MYLAN	**5MG**	**N74226 001**
				MAY 10, 1994
AB			**10MG**	**N74226 002**
				MAY 10, 1994
		GLUCOTROL		
AB		PFIZER	**5MG**	**N17783 001**
				MAY 08, 1984
AB	+		**10MG**	**N17783 002**
				MAY 08, 1984

TABLET, EXTENDED RELEASE; ORAL

		GLUCOTROL XL		
	+	PFIZER	5MG	N20329 001
				APR 26, 1994
	+		10MG	N20329 002
				APR 26, 1994

GLUTETHIMIDE

TABLET; ORAL

		GLUTETHIMIDE		
AA		HALSEY	250MG	N89458 001
				OCT 10, 1986
			250MG	N89458 001
				OCT 10, 1986
AA		LANNETT	250MG	N83475 001
AA			500MG	N85571 001
	@		250MG	N83475 001
	@		500MG	N85571 001

GLYCOPYRROLATE

INJECTABLE; INJECTION

		GLYCOPYRROLATE		
AP		FUJISAWA	0.2MG/ML	N88475 001
				JUN 12, 1984
	@		0.2MG/ML	N88475 001
				JUN 12, 1984

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

			A.P.L.		
> DLT <	AP	+	WYETH AYERST	20,000 UNITS/VIAL	N17055 003
> ADD <		+		20,000 UNITS/VIAL	N17055 003
			CHORIONIC GONADOTROPIN		
	AP		FUJISAWA	5,000 UNITS/VIAL	N17067 001
	AP			20,000 UNITS/VIAL	N17067 003
		@		5,000 UNITS/VIAL	N17067 001
		@		20,000 UNITS/VIAL	N17067 003
> DLT <	AP		STERIS	20,000 UNITS/VIAL	N17016 004
> DLT <		+		15,000 UNITS/VIAL	N17016 010
> DLT <					FEB 15, 1985
> ADD <		@		15,000 UNITS/VIAL	N17016 010
> ADD <					FEB 15, 1985
> ADD <		@		20,000 UNITS/VIAL	N17016 004

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

		NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN		
AT		PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001
				AUG 31, 1982

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

		NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN		
	@	PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62383 001
				AUG 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

		KYTRIL		
	+	SMITHKLINE BEECHAM	EQ 3MG BASE/ML	N20239 001
				DEC 29, 1993
	+		EQ 1MG BASE/ML	N20239 002
				MAR 11, 1994
	@		EQ 3MG BASE/ML	N20239 001
				DEC 29, 1993

GUANABENZ ACETATE

TABLET; ORAL

		GUANABENZ ACETATE		
AB		COPLEY PHARM	EQ 4MG BASE	N74267 001
				JUN 01, 1994
AB			EQ 8MG BASE	N74267 002
				JUN 01, 1994
AB		WATSON LABS	EQ 4MG BASE	N74025 001
				FEB 28, 1994
AB			EQ 8MG BASE	N74025 002
				FEB 28, 1994
		WYTENSIN		
AB		WYETH AYERST	EQ 4MG BASE	N18587 001
				SEP 07, 1982
AB	+		EQ 8MG BASE	N18587 002
				SEP 07, 1982

HEPARIN CALCIUM

INJECTABLE; INJECTION

		CALCIPARINE		
	+	CHOAY	25,000 UNITS/ML	N18237 001
	+	DUPONT	25,000 UNITS/ML	N18237 001

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HCL			
> DLT >	**AA**	AMIDE PHARM	**25MG**	**N88560 001**	
> DLT >				OCT 04, 1984	
> DLT >	**AA**		**50MG**	**N88649 001**	
> DLT >				OCT 18, 1984	
> ADD >		@	25MG	N88560 001	
> ADD >				OCT 04, 1984	
> ADD >		@	50MG	N88649 001	
> ADD >				OCT 18, 1984	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

		RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE		
	BP	DANBURY PHARMA	25MG;15MG;0.1MG	N87556 001
		@	25MG;15MG;0.1MG	N87556 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL

		HYDROCHLOROTHIAZIDE		
> DLT >	**AB**	WEST WARD	**25MG**	**N84899 001**
> ADD >		@ WEST WARD PHARM	25MG	N84899 001
	AB	ZENITH	**50MG**	**N84658 001**
		@ ZENITH LABS	50MG	N84658 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

		NORMOZIDE		
		SCHERING	25MG;100MG	N19046 001
				APR 06, 1987
			25MG;200MG	N19046 002
				APR 06, 1987
		+	25MG;300MG	N19046 003
				APR 06, 1987
		@	25MG;100MG	N19046 001
				APR 06, 1987
		@	25MG;200MG	N19046 002
				APR 06, 1987
		@	25MG;300MG	N19046 003
				APR 06, 1987

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

		HYDROCHLOROTHIAZIDE W/ RESERPINE		
	BP	ROXANE	50MG;0.125MG	N84603 001
		@	50MG;0.125MG	N84603 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

		DYAZIDE		
	AB	+ SMITHKLINE BEECHAM	**25MG;50MG**	**N16042 002**
			25MG;37.5MG	N16042 003
				MAR 03, 1994
		@	25MG;50MG	N16042 002
		TRIAMTERENE AND HYDROCHLOROTHIAZIDE		
	AB	GENEVA PHARMS	**25MG;50MG**	**N73191 001**
				JUL 31, 1991
		+	25MG;50MG	N73191 001
				JUL 31, 1991

HYDROCORTISONE

CREAM; TOPICAL

		HYDROCORTISONE		
	AT	LEMMON	**1%**	**N85191 001**
		@	1%	N85191 001
	AT	PHARMAFAIR	**1%**	**N87838 001**
				JUL 28, 1982
		@	1%	N87838 001
				JUL 28, 1982

ENEMA; RECTAL

		CORTENEMA		
		+ SOLVAY	100MG/60ML	N16199 001
		HYDROCORTISONE		
	AT	COPLEY PHARM	**100MG/60ML**	**N74171 001**
				MAY 27, 1994

GEL; TOPICAL

		NUTRACORT		
	AT	+ GALDERMA	**1%**	**N84698 001**
		@	1%	N84698 001
		PENECORT		
	AT	ALLERGAN HERBERT	**1%**	**N88215 001**
				JUN 06, 1984

HYDROCORTISONE

GEL; TOPICAL
PENECORT
\+ ALLERGAN HERBERT 1% N88215 001 JUN 06, 1984

LOTION; TOPICAL
HYDROCORTISONE
AT CLAY PARK 1% N85663 001
@ 1% N85663 001

OINTMENT; TOPICAL
HYDROCORTISONE
AT CLAY PARK 1% N85028 001
@ 1% N85028 001

TABLET; ORAL
HYDROCORTISONE
BP DANBURY PHARMA 20MG N80355 001
@ 20MG N80355 001
BP INWOOD 20MG N80732 001
@ INWOOD LABS 20MG N80732 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
AT PHARMAFAIR 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62394 001 SEP 29, 1982
@ 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62394 001 SEP 29, 1982

SUSPENSION; OTIC
OTICAIR
AT PHARMAFAIR 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62399 001 NOV 18, 1982
@ 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62399 001 NOV 18, 1982

HYDROCORTISONE ACETATE

CREAM; TOPICAL
HYDROCORTISONE ACETATE
AT PARKE DAVIS 1% N89914 001 JAN 03, 1989
@ 1% N89914 001 JAN 03, 1989

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE
BP STERIS 50MG/ML N85214 001
@ 50MG/ML N85214 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
\+ BROCADES PHARMA 0.1% N18514 001 MAR 31, 1982
\+ YAMANOUCHI 0.1% N18514 001 MAR 31, 1982

OINTMENT; TOPICAL
LOCOID
@ BROCADES PHARMA 0.1% N18652 001 OCT 29, 1982
@ YAMANOUCHI 0.1% N18652 001 OCT 29, 1982

SOLUTION; TOPICAL
LOCOID
\+ BROCADES PHARMA 0.1% N19116 001 FEB 25, 1987
\+ YAMANOUCHI 0.1% N19116 001 FEB 25, 1987

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT
AP ABBOTT EQ 250MG BASE/VIAL N89578 001 APR 11, 1989
AP EQ 500MG BASE/VIAL N89579 001 APR 11, 1989
AP EQ 1GM BASE/VIAL N89580 001 APR 11, 1989

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-HYDROCORT			
	@ ABBOTT	EQ 250MG BASE/VIAL	N89578 001	APR 11, 1989
	@	EQ 500MG BASE/VIAL	N89579 001	APR 11, 1989
	@	EQ 1GM BASE/VIAL	N89580 001	APR 11, 1989

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

	DILAUDID-HP			
	+ KNOLL PHARM	250MG/VIAL	N19034 002	AUG 04, 1994

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

> ADD >	**HYDROXYCHLOROQUINE SULFATE**			
> ADD > AB	COPLEY PHARM	**200MG**	**N40081 001**	SEP 30, 1994
> ADD >				
	PLAQUENIL			
> ADD > AB	+ STERLING WINTHROP	**200MG**	**N09768 001**	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

	DELALUTIN			
AO	+ SQUIBB	**125MG/ML**	**N10347 004**	
AO		**125MG/ML**	**N16911 001**	
AO	+	**250MG/ML**	**N10347 002**	
AO		**250MG/ML**	**N16911 002**	
	@	125MG/ML	N10347 004	
	@	125MG/ML	N16911 001	
	@	250MG/ML	N10347 002	
	@	250MG/ML	N16911 002	
	HYDROXYPROGESTERONE CAPROATE			
AO	STERIS	**125MG/ML**	**N17439 001**	
AO	+	**125MG/ML**	**N17439 001**	
AO		**250MG/ML**	**N17439 002**	
	+	250MG/ML	N17439 002	

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL			
AP	SMITH NEPHEW SOLOPAK	**25MG/ML**	**N87591 001**	
AP		**50MG/ML**	**N87593 001**	
AP		**50MG/ML**	**N87595 001**	
AP	SOLOPAK	**25MG/ML**	**N87591 001**	
AP		**50MG/ML**	**N87593 001**	
AP		**50MG/ML**	**N87595 001**	
	ORGATRAX			
AP	ORGANON	**25MG/ML**	**N87014 001**	
AP		**50MG/ML**	**N87014 002**	
	@	25MG/ML	N87014 001	
	@	50MG/ML	N87014 002	

TABLET; ORAL

	HYDROXYZINE HCL			
AB	ROYCE LABS	**10MG**	**N81149 001**	MAR 18, 1994
AB		**25MG**	**N81150 001**	MAR 18, 1994
AB		**50MG**	**N81151 001**	MAR 18, 1994

IMIGLUCERASE

INJECTABLE; INJECTION

	CEREZYME			
	+ GENZYME	200 UNITS/VIAL	N20367 001	MAY 23, 1994

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

	OCTREOSCAN			
	MALLINCKRODT	3mCi/ML	N20314 001	JUN 02, 1994

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
AB	CHELSEA	**25MG**	**N18690 001**	JUL 31, 1984

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN		
AB	CHELSEA	50MG	N18690 002 JUL 31, 1984
	@ CHELSEA LABS	25MG	N18690 001 JUL 31, 1984
	@	50MG	N18690 002 JUL 31, 1984

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION

	HUMULIN R		
	+ LILLY	500 UNITS/ML	N18780 004 MAR 31, 1994

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

	BAXTER	10GM/100ML	N16717 001
	@	10GM/100ML	N16717 001

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION

	IOBENGUANE SULFATE I 131		
	CIS	2.3mCi/ML	N20084 001 MAR 25, 1994

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

	RENOVUE-65		
	+ BRACCO DXS	65%	N17902 001
	+ SQUIBB	65%	N17902 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

	CHOLOGRAFIN MEGLUMINE		
	+ BRACCO DXS	10.3%	N09321 007

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

	CHOLOGRAFIN MEGLUMINE		
	+ BRACCO DXS	52%	N09321 003
	+ SQUIBB	10.3%	N09321 007
	+	52%	N09321 003

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

	CHOLOGRAFIN SODIUM		
	@ BRACCO DXS	20%	N09321 001
	@ SQUIBB	20%	N09321 001

IODOHIPPURATE SODIUM, I-123

INJECTABLE; INJECTION

	NEPHROFLOW		
	MEDI PHYSICS	1mCi/ML	N18289 001 DEC 28, 1984
	@	1mCi/ML	N18289 001 DEC 28, 1984

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

	CHOLOVUE		
	@ BRACCO DXS	9.9%	N18077 001
	@	40.3%	N18076 001
	@ SQUIBB	9.9%	N18077 001
	@	40.3%	N18076 001

IOHEXOL

SOLUTION; URETHRAL

	OMNIPAQUE 70		
	+ STERLING WINTHROP	15.1%	N18956 007 JUN 01, 1994

IPODATE CALCIUM

GRANULE; ORAL

	ORAGRAFIN CALCIUM		
	BRACCO DXS	3GM/PACKET	N12968 001

IPODATE CALCIUM

GRANULE; ORAL
ORAGRAFIN CALCIUM
SQUIBB 3GM/PACKET N12968 001

IPODATE SODIUM

CAPSULE; ORAL
ORAGRAFIN SODIUM
AA BRACCO DXS 500MG N12967 001
AA SQUIBB 500MG N12967 001

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE
> ADD > AN INHALON 99.9% N74416 001
> ADD > SEP 30, 1994

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL
RIFATER
+ MARION MERRELL DOW 50MG;300MG;120MG N50705 001
MAY 31, 1994

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION
ISUPREL
+ STERLING WINTHROP 0.113MG/INH N11178 001
+ 0.131MG/INH N11178 001

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISMO
AB + WYETH 20MG N19091 001
DEC 30, 1991
BX + 20MG N19091 001
DEC 30, 1991

MONOKET
AB SCHWARZ PHARMA 20MG N20215 001
JUN 30, 1993

ISOSORBIDE MONONITRATE

TABLET; ORAL
MONOKET
BX SCHWARZ PHARMA 20MG N20215 001
JUN 30, 1993

ISRADIPINE

CAPSULE; ORAL
DYNACIRC
SANDOZ 5MG N19546 002
DEC 20, 1990
+ 5MG N19546 002
DEC 20, 1990

TABLET, EXTENDED RELEASE; ORAL
DYNACIRC CR
+ SANDOZ 5MG N20336 001
JUN 01, 1994
+ 10MG N20336 002
JUN 01, 1994

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
+ APOTHECON EQ 500MG BASE N61911 001
EQ 500MG BASE N62726 001
MAR 06, 1987
@ EQ 500MG BASE N60516 001
@ EQ 500MG BASE N61911 001
+ EQ 500MG BASE N62726 001
MAR 06, 1987
AB + BRISTOL EQ 500MG BASE N60516 001

INJECTABLE; INJECTION
KANTREX
AP + APOTHECON EQ 75MG BASE/2ML N61655 003
AP EQ 75MG BASE/2ML N61901 003
AP + EQ 75MG BASE/2ML N61901 003
AP + EQ 500MG BASE/2ML N61655 001
AP EQ 500MG BASE/2ML N61901 001
AP + EQ 500MG BASE/2ML N61901 001
AP + EQ 1GM BASE/3ML N61655 002
AP EQ 1GM BASE/3ML N61901 002
AP + EQ 1GM BASE/3ML N61901 002

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANTREX			
	@ APOTHECON	EQ 75MG BASE/2ML	N61655 003	
	@	EQ 75MG BASE/2ML	N62564 001	
			SEP 21, 1984	
	@	EQ 500MG BASE/2ML	N61655 001	
	@	EQ 500MG BASE/2ML	N62564 002	
			SEP 21, 1984	
	@	EQ 1GM BASE/3ML	N61655 002	
	@	EQ 1GM BASE/3ML	N62564 003	
			SEP 21, 1984	
AP	BRISTOL	**EQ 75MG BASE/2ML**	**N62564 001**	
			SEP 21, 1984	
AP		**EQ 500MG BASE/2ML**	**N62564 002**	
			SEP 21, 1984	
AP		**EQ 1GM BASE/3ML**	**N62564 003**	
			SEP 21, 1984	
	KLEBCIL			
	@ KING PHARMS	EQ 75MG BASE/2ML	N62170 001	
	@	EQ 500MG BASE/2ML	N62170 002	
	@	EQ 1GM BASE/3ML	N62170 003	
	@ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001	
	@	EQ 500MG BASE/2ML	N62170 002	
	@	EQ 1GM BASE/3ML	N62170 003	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM		
AP	ELKINS SINN	**EQ 100MG BASE/VIAL**	**N81224 001**
			JUN 03, 1994
+	IMMUNEX	EQ 3MG BASE/ML	N08107 001
	@	EQ 3MG BASE/ML	N08107 001

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAGAN			
AT	+ ALLERGAN	**0.25%**	**N19814 001**	
			JUN 28, 1989	
AT	+	**0.5%**	**N19219 002**	
			DEC 19, 1985	
	LEVOBUNOLOL HCL			
AT	BAUSCH AND LOMB	**0.25%**	**N74307 001**	
			MAR 04, 1994	

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	LEVOBUNOLOL HCL			
AT	BAUSCH AND LOMB	**0.5%**	**N74326 001**	
			MAR 04, 1994	

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ARESTOCAINE HCL W/ LEVONORDEFRIN			
AP	CARLISLE	**0.05MG/ML;2%**	**N85010 001**	
	@ SOLVAY	0.05MG/ML;2%	N85010 001	

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

	MYLOCAINE			
AT	PENNEX	**4%**	**N87881 001**	
			NOV 18, 1982	
	@ PENNEX PHARMS	4%	N87881 001	
			NOV 18, 1982	
	PEDIATRIC LTA KIT			
AT	ABBOTT	**2%**	**N88572 001**	
			JUL 31, 1984	
	@	2%	N88572 001	
			JUL 31, 1984	

LIOTRIX (T4;T3)

TABLET; ORAL

	EUTHROID-0.5		
	PARKE DAVIS	0.03MG;0.0075MG	N16680 001
	@	0.03MG;0.0075MG	N16680 001
	EUTHROID-1		
	PARKE DAVIS	0.06MG;0.015MG	N16680 002
	@	0.06MG;0.015MG	N16680 002
	EUTHROID-2		
	PARKE DAVIS	0.12MG;0.03MG	N16680 003
	@	0.12MG;0.03MG	N16680 003
	EUTHROID-3		
+	PARKE DAVIS	0.18MG;0.045MG	N16680 004
	@	0.18MG;0.045MG	N16680 004

LISINOPRIL

TABLET; ORAL

	PRINIVIL				
AB	MERCK	2.5MG	N19558 006		
			JAN 28, 1994		
	ZESTRIL				
AB	ZENECA	2.5MG	N19777 005		
			APR 29, 1993		

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

	LITHOBID				
	+ CIBA	300MG	N18027 001		
	@	300MG	N18027 001		

LORAZEPAM

INJECTABLE; INJECTION

	ATIVAN				
AP	+ WYETH AYERST	2MG/ML	N18140 001		
AP	+	4MG/ML	N18140 002		
	LORAZEPAM				
AP	ABBOTT	2MG/ML	N74280 001		
			MAY 27, 1994		
AP		2MG/ML	N74282 001		
			MAY 27, 1994		
AP		4MG/ML	N74280 002		
			MAY 27, 1994		
AP		4MG/ML	N74282 002		
			MAY 27, 1994		
AP	STERIS	2MG/ML	N74276 001		
			APR 15, 1994	> ADD >	
AP		4MG/ML	N74276 002	> ADD >	
			APR 15, 1994	> ADD >	
AP	STERLING WINTHROP	2MG/ML	N74243 001	> ADD >	
			APR 12, 1994	> ADD >	
AP		2MG/ML	N74300 001		
			APR 12, 1994	> ADD >	
AP		4MG/ML	N74243 002	> ADD >	
			APR 12, 1994	> ADD >	

TABLET; ORAL

	LORAZEPAM				
AB	WARNER CHILCOTT	1MG	N71038 001		
			JAN 12, 1988		

LORAZEPAM

TABLET; ORAL

	LORAZEPAM				
AB	WARNER CHILCOTT	2MG	N71039 001		
			JAN 12, 1988		
	@	1MG	N71038 001		
			JAN 12, 1988		
	@	2MG	N71039 001		
			JAN 12, 1988		

MAGNESIUM SULFATE

INJECTABLE; INJECTION

	MAGNESIUM SULFATE IN PLASTIC CONTAINER				
	ABBOTT	4GM/100ML	N20309 001		
			JUN 24, 1994		
		80MG/ML	N20309 002		
			JUN 24, 1994		

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA				
	UPJOHN	150MG/ML	N20246 001		
			OCT 29, 1992		
	+	150MG/ML	N20246 001		
			OCT 29, 1992		

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

	HUMEGON				
	ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001		
			SEP 01, 1994		
		150 IU/VIAL;150 IU/VIAL	N20328 002		
			SEP 01, 1994		
	PERGONAL				
	+ SERONO	75 IU/AMP;75 IU/AMP	N17646 001		
	+	150 IU/AMP;150 IU/AMP	N17646 002		
			MAY 20, 1985		

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
ARESTOCAINE HCL

AP	CARLISLE	3%	N84777 002 APR 18, 1982
@	SOLVAY	3%	N84777 002 APR 18, 1982

MEPROBAMATE

TABLET; ORAL
MEPRIAM

AA	LEMMON	400MG	N16069 001
@		400MG	N16069 001

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

AP	FUJISAWA	EQ 10MG BASE/ML	N80431 001
@		EQ 10MG BASE/ML	N80431 001

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE

AB	MIKART	25MG	N40062 001 JAN 27, 1994
AB		50MG	N40062 002 JAN 27, 1994

METHDILAZINE

TABLET, CHEWABLE; ORAL
TACARYL

	WESTWOOD SQUIBB	3.6MG	N11950 009
@		3.6MG	N11950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL
TACARYL

	WESTWOOD SQUIBB	4MG/5ML	N11950 007

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL
TACARYL

@	WESTWOOD SQUIBB	4MG/5ML	N11950 007

TABLET; ORAL
TACARYL

	WESTWOOD SQUIBB	8MG	N11950 006
@		8MG	N11950 006

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX PFS

AP	ADRIA	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986
@	PHARMACIA	EQ 25MG BASE/ML	N89180 001 JAN 03, 1986

TABLET; ORAL
METHOTREXATE SODIUM

AB	ROXANE	EQ 2.5MG BASE	N40054 001 AUG 01, 1994

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
PAMINE

AA	BRADLEY	2.5MG	N08848 001
AA	UPJOHN	2.5MG	N08848 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP	ABBOTT	EQ 40MG BASE/VIAL	N89573 001 FEB 22, 1991
AP		EQ 125MG BASE/VIAL	N89574 001 FEB 22, 1991
AP		EQ 500MG BASE/VIAL	N89575 001 FEB 22, 1991
@		EQ 40MG BASE/VIAL	N89573 001 FEB 22, 1991
@		EQ 125MG BASE/VIAL	N89574 001 FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	A-METHAPRED			
	@ ABBOTT	EQ 500MG BASE/VIAL	N89575 001	
			FEB 22, 1991	
	METHYLPREDNISOLONE			
AP	ORGANON	**EQ 500MG BASE/VIAL**	**N87535 001**	
			JUN 25, 1982	
AP		**EQ 1GM BASE/VIAL**	**N87535 002**	
			JUN 25, 1982	
	@	EQ 500MG BASE/VIAL	N87535 001	
			JUN 25, 1982	
	@	EQ 1GM BASE/VIAL	N87535 002	
			JUN 25, 1982	

METHYLTESTOSTERONE

TABLET; BUCCAL/SUBLINGUAL

	METHYLTESTOSTERONE			
	PRIVATE FORM	5MG	N83836 001	
	@ PVT FORM	5MG	N83836 001	
BP	TABLICAPS	10MG	N85125 001	
	@	10MG	N85125 001	

TABLET; ORAL

	METHYLTESTOSTERONE			
BP	DANBURY PHARMA	10MG	N80933 001	> ADD >
BP		25MG	N80931 001	> ADD >
	@	10MG	N80933 001	
	@	25MG	N80931 001	
BP	PUREPAC	10MG	N80475 002	
BP		25MG	N80475 003	
	@ PUREPAC PHARM	10MG	N80475 002	
	@	25MG	N80475 003	
BP	TABLICAPS	10MG	N80313 001	
BP		25MG	N85270 001	
	@	10MG	N80313 001	
	@	25MG	N85270 001	
BP	WEST WARD	10MG	N84331 001	
BP		25MG	N84331 002	
	@ WEST WARD PHARM	10MG	N84331 001	
	@	25MG	N84331 002	

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

	MAXOLON		
AB	KING PHARMS	**EQ 10MG BASE**	**N70106 001**
			MAR 04, 1986
AB	SMITHKLINE BEECHAM	**EQ 10MG BASE**	**N70106 001**
			MAR 04, 1986

METOPROLOL TARTRATE

TABLET; ORAL

	METOPROLOL TARTRATE		
AB	APOTHECON	**50MG**	**N74258 001**
			JAN 27, 1994
AB		**100MG**	**N74258 002**
			JAN 27, 1994
AB	COPLEY PHARM	**50MG**	**N74333 001**
			JAN 27, 1994
AB		**100MG**	**N74333 002**
			JAN 27, 1994
AB	GENEVA PHARMS	**50MG**	**N73288 001**
			MAR 25, 1994
AB		**100MG**	**N73289 001**
			MAR 25, 1994
AB	NOVOPHARM	**50MG**	**N74143 001**
			SEP 30, 1994
AB		**100MG**	**N74143 002**
			SEP 30, 1994
AB	PUREPAC PHARM	**50MG**	**N74380 001**
			JUL 29, 1994
AB		**100MG**	**N74380 002**
			JUL 29, 1994
AB	WATSON LABS	**50MG**	**N74217 001**
			MAY 27, 1994
AB		**100MG**	**N74217 002**
			MAY 27, 1994

MILRINONE LACTATE

INJECTABLE; INJECTION

	MILRINONE LACTATE		
*	STERLING WINTHROP	EQ 1MG BASE/ML	N19436 001
			DEC 31, 1987
	PRIMACOR		
+	STERLING WINTHROP	EQ 1MG BASE/ML	N19436 001
			DEC 31, 1987

MILRINONE LACTATE

INJECTABLE; INJECTION
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

@	STERLING WINTHROP	EQ 10MG BASE/100ML	N20343 001 AUG 09, 1994
@		EQ 15MG BASE/100ML	N20343 002 AUG 09, 1994
+		EQ 20MG BASE/100ML	N20343 003 AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCIN

@	LEDERLE	EQ 50MG BASE	N50451 003 AUG 10, 1982
@		EQ 100MG BASE	N50451 002 AUG 10, 1982

MINOCYCLINE HCL

	LEDERLE	EQ 50MG BASE	N50451 003 AUG 10, 1982
		EQ 100MG BASE	N50451 002 AUG 10, 1982

NADOLOL

TABLET; ORAL
CORGARD

AB	SQUIBB	120MG	N18063 003
AB		120MG	N18064 003
AB	+	160MG	N18063 004
AB		160MG	N18064 004

NADOLOL

AB	COPLEY PHARM	80MG	N74368 001 AUG 31, 1994
AB		120MG	N74368 002 AUG 31, 1994
AB		160MG	N74368 003 AUG 31, 1994

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N61984 001

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 1GM BASE/VIAL	N61984 002
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 4GM BASE/VIAL	N61984 005
AP	BRISTOL	EQ 500MG BASE/VIAL	N61984 001
AP		EQ 1GM BASE/VIAL	N61984 002
AP		EQ 2GM BASE/VIAL	N61984 003
AP		EQ 4GM BASE/VIAL	N61984 005

UNIPEN

AP	WYETH AYERST	EQ 10GM BASE/VIAL	N50320 005
@		EQ 20GM BASE/VIAL	N50320 006

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAFAZAIR

AT	BAUSCH AND LOMB	0.1%	N40073 001 MAY 25, 1994
AT	PHARMAFAIR	0.1%	N88101 001 APR 15, 1983
@		0.1%	N88101 001 APR 15, 1983

NAPROXEN

SUSPENSION; ORAL
NAPROSYN

AB	+ SYNTEX	25MG/ML	N18965 001 MAR 23, 1987

NAPROXEN

AB	ROXANE	25MG/ML	N74190 001 MAR 30, 1994

TABLET; ORAL
NAPROSYN

AB	SYNTEX	500MG	N17581 004 APR 15, 1982
AB	+	500MG	N17581 004 APR 15, 1982

NAPROXEN

AB	ROXANE	250MG	N74211 001 FEB 28, 1994
AB		375MG	N74211 002 FEB 28, 1994

NAPROXEN

TABLET; ORAL
NAPROXEN

AB	ROXANE	500MG	N74211 003 FEB 28, 1994

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	COPLEY PHARM	EQ 250MG BASE	N74289 001 JAN 27, 1994
AB		EQ 500MG BASE	N74289 002 JAN 27, 1994
AB	MYLAN	EQ 250MG BASE	N74367 001 AUG 31, 1994
AB		EQ 500MG BASE	N74367 002 AUG 31, 1994

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA	LANNETT	EQ 350MG BASE	N60607 001
@		EQ 350MG BASE	N60607 001

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
HABITROL

BC	BASEL PHARMS	7MG/24HR	N20076 001 NOV 27, 1991
BC +		7MG/24HR	N20076 001 NOV 27, 1991
BC		14MG/24HR	N20076 002 NOV 27, 1991
BC +		14MG/24HR	N20076 002 NOV 27, 1991
BC		21MG/24HR	N20076 003 NOV 27, 1991
BC +		21MG/24HR	N20076 003 NOV 27, 1991

NITROFURANTOIN

TABLET; ORAL
FURALAN

AB	LANNETT	50MG	N80017 001
AB		100MG	N80017 002
@		50MG	N80017 001
@		100MG	N80017 002

NITROFURAZONE

OINTMENT; TOPICAL
NITROFURAZONE

AT	LANNETT	0.2%	N84393 001
@		0.2%	N84393 001

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

AP	INTL MEDICATION	5MG/ML	N70026 001 SEP 10, 1985
@		5MG/ML	N70026 001 SEP 10, 1985

NITRONAL

+	BOSKAMP	1MG/ML	N18672 001 AUG 30, 1983
@	G POHL BOSKAMP	1MG/ML	N18672 001 AUG 30, 1983

NITROSTAT

AP	PARKE DAVIS	5MG/ML	N70863 001 JAN 08, 1987
		10MG/ML	N70871 001 JAN 08, 1987
		10MG/ML	N70872 001 JAN 08, 1987
@		5MG/ML	N70863 001 JAN 08, 1987
@		10MG/ML	N70871 001 JAN 08, 1987
@		10MG/ML	N70872 001 JAN 08, 1987

NORETHINDRONE

TABLET; ORAL
NORLUTIN
+ PARKE DAVIS 5MG N10895 002
@ 5MG N10895 002

NYSTATIN

SUSPENSION; ORAL
NYSTATIN
AA BAUSCH AND LOMB 100,000 UNITS/ML N64042 001 FEB 28, 1994
AA PHARMAFAIR 100,000 UNITS/ML N62541 001 JAN 16, 1985
@ 100,000 UNITS/ML N62541 001 JAN 16, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
MYCOLOG-II
AT + APOTHECON 100,000 UNITS/GM;0.1% N60576 002 MAY 01, 1985
AT 100,000 UNITS/GM;0.1% N62606 001 MAY 15, 1985
AT + SQUIBB 100,000 UNITS/GM;0.1% N60576 002 MAY 01, 1985
AT 100,000 UNITS/GM;0.1% N62606 001 MAY 15, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE
AT BARRE 100,000 UNITS/GM;0.1% N63010 001 DEC 20, 1988
@ 100,000 UNITS/GM;0.1% N63010 001 DEC 20, 1988
B* CLAY PARK 100,000 UNITS/GM;0.1% N62186 002 JUN 06, 1985
@ 100,000 UNITS/GM;0.1% N62186 002 JUN 06, 1985
AT PHARMAFAIR 100,000 UNITS/GM;0.1% N62657 001 JUL 30, 1986
@ 100,000 UNITS/GM;0.1% N62657 001 JUL 30, 1986

OINTMENT; TOPICAL
NYSTATIN-TRIAMCINOLONE ACETONIDE
AT PHARMADERM 100,000 UNITS/GM;0.1% N62603 001 OCT 09, 1985

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
NYSTATIN-TRIAMCINOLONE ACETONIDE
@ PHARMADERM 100,000 UNITS/GM;0.1% N62603 001 OCT 09, 1985

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PRILOSEC
+ ASTRA MERCK 20MG N19810 001 SEP 14, 1989
+ MERCK 20MG N19810 001 SEP 14, 1989

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL
DISIPAL
3M 50MG N10653 001
@ 50MG N10653 001

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
SMITHKLINE BEECHAM EQ 30MG BASE N20031 003 DEC 29, 1992
+ EQ 30MG BASE N20031 003 DEC 29, 1992

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
@ APOTHECON 1,000,000 UNITS/VIAL N60362 001
@ 5,000,000 UNITS/VIAL N60362 003
@ 10,000,000 UNITS/VIAL N60362 004
@ 20,000,000 UNITS/VIAL N60362 002
AP SQUIBB 1,000,000 UNITS/VIAL N60362 001
AP 5,000,000 UNITS/VIAL N60362 003
AP 10,000,000 UNITS/VIAL N60362 004
AP 20,000,000 UNITS/VIAL N60362 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	BETAPEN-VK			
	@ APOTHECON	EQ 125MG BASE/5ML	N61149 001	
	@	EQ 250MG BASE/5ML	N61149 002	
AA	**BRISTOL**	**EQ 125MG BASE/5ML**	**N61149 001**	
AA		**EQ 250MG BASE/5ML**	**N61149 002**	
> ADD >	**VEETIDS**			
> ADD > **AA**	APOTHECON	**EQ 125MG BASE/5ML**	**N61410 001**	
> ADD > **AA**		**EQ 250MG BASE/5ML**	**N61410 002**	

TABLET; ORAL

	UTICILLIN VK			
AB	**UPJOHN**	**EQ 500MG BASE**	**N61651 002**	
	@	EQ 500MG BASE	N61651 002	

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

	PENTACARINAT			
AP	RHONE POULENC RORER	**300MG/VIAL**	**N73447 001**	APR 28, 1994

PENTOBARBITAL SODIUM

CAPSULE; ORAL

	PENTOBARBITAL SODIUM			
AA	**LANNETT**	**50MG**	**N85937 001**	
AA		**100MG**	**N85915 001**	
	@	50MG	N85937 001	
	@	100MG	N85915 001	

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

	PHENDIMETRAZINE TARTRATE			
AA	ZENITH	**35MG**	**N85611 001**	
	@ ZENITH LABS	35MG	N85611 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
AA	**LANNETT**	**30MG**	**N87022 001**	FEB 03, 1983

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	PHENTERMINE HCL			
	@ LANNETT	30MG	N87022 001	FEB 03, 1983

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE VC PLAIN			
AA	PENNEX	**5MG/5ML;6.25MG/5ML**	**N88897 001**	JAN 04, 1985
	@ PENNEX PHARMS	5MG/5ML;6.25MG/5ML	N88897 001	JAN 04, 1985

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

	DIPHENYLAN SODIUM			
BX	**LANNETT**	**100MG**	**N80857 002**	
		30MG	**N80857 001**	
	@	30MG	N80857 001	
	@	100MG	N80857 002	

PHYTONADIONE

INJECTABLE; INJECTION

	PHYTONADIONE			
BP	**SMITHKLINE BEECHAM**	**1MG/0.5ML**	**N84060 001**	
BP		**10MG/ML**	**N84060 002**	
	@	1MG/0.5ML	N84060 001	
	@	10MG/ML	N84060 002	

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

	SALAGEN			
	+ MGI	5MG	N20237 001	MAR 22, 1994

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	MUTUAL PHARM	5MG	N74063 001	JAN 27, 1994
AB		10MG	N74063 002	JAN 27, 1994

PIPERAZINE CITRATE

SYRUP; ORAL
VERMIDOL

AA	SOLVAY	EQ 500MG BASE/5ML	N80992 001	
	@	EQ 500MG BASE/5ML	N80992 001	

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOVOPHARM	10MG	N73637 001	JAN 28, 1994
AB		20MG	N73638 001	JAN 28, 1994

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
AEROSPORIN

>_DLT_>	AP	*	BURROUGHS WELLCOME	500,000 UNITS/VIAL	N62036 001
>_ADD_>	AP	+		EQ 500,000 U BASE/VIAL	N62036 001

POLYMIXIN B SULFATE

>_DLT_>	AP		PFIZER	500,000 UNITS/VIAL	N60716 001
>_ADD_>	AP			EQ 500,000 U BASE/VIAL	N60716 001

POLYMYXIN B SULFATE

>_ADD_>	AP		PHARMA TEK	EQ 500,000 U BASE/VIAL	N63000 001
>_ADD_>					SEP 30, 1994

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N87885 001	FEB 03, 1983

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

	@ FUJISAWA	2MEQ/ML	N87885 001	FEB 03, 1983

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

BX	BUNDY	5MG	N83675 001	
	@	5MG	N83675 001	
BX	ICN	5MG	N80236 001	
	@	5MG	N80236 001	
BX	INWOOD	5MG	N80748 001	
	@ INWOOD LABS	5MG	N80748 001	
BX	TABLICAPS	5MG	N85170 001	
	@	5MG	N85170 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
METIMYD

AT	+ SCHERING	0.5%;10%	N10210 002	

VASOCIDIN

AT	IOLAB	0.5%;10%	N88791 001	OCT 05, 1984

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDAIR FORTE

AT	PHARMAFAIR	EQ 0.9% PHOSPHATE	N88165 001	MAR 28, 1983
	@	EQ 0.9% PHOSPHATE	N88165 001	MAR 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	N40065 001	JUL 29, 1994
AT		EQ 0.9% PHOSPHATE	N40070 001	JUL 29, 1994

PREDNISONE

TABLET; ORAL
PREDNISONE

	@	1ST TX	5MG	N80371 001
BX		BUNDY	5MG	N83676 001
	@		5MG	N83676 001
BX		DANBURY PHARMA	50MG	N86867 001
	@		50MG	N86867 001
	@	FERRANTE	2.5MG	N80563 001
	@		5MG	N80563 002
BX		FIRST TX	5MG	N80371 001
BX		ICN	5MG	N80237 001
	@		5MG	N80237 001
BX		INWOOD	1MG	N80328 001
BX			2.5MG	N80306 001
	@	INWOOD LABS	1MG	N80328 001
	@		2.5MG	N80306 001
BX		MK	2.5MG	N80563 001
BX			5MG	N80563 002
BX		NYLOS	5MG	N85115 001
	@		5MG	N85115 001
BX		REXALL	5MG	N80232 001
	@		5MG	N80232 001
BX		SPERTI	1MG	N80359 001
BX			2.5MG	N80359 002
BX			5MG	N80359 003
	@		1MG	N80359 001
	@		2.5MG	N80359 002
	@		5MG	N80359 003
BX		WHITE TOWNE PAULSEN	20MG	N84913 002
	@	WHITEWORTH TOWNE	20MG	N84913 002

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE PLAIN

AA		PENNEX	**6.25MG/5ML**	**N87953 001 NOV 15, 1982**
	@	PENNEX PHARMS	6.25MG/5ML	N87953 001 NOV 15, 1982

TABLET; ORAL
PROMETHAZINE HCL

BP		TABLICAPS	12.5MG	N84080 001
BP			25MG	N84027 001
	@		12.5MG	N84080 001
	@		25MG	N84027 001

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
REMSED

BP		DUPONT	25MG	N83176 002
	@	DUPONT MERCK	25MG	N83176 002

PROPANTHELINE BROMIDE

TABLET; ORAL
PRO-BANTHINE

AA		ROBERTS LABS	**7.5MG**	**N08732 003**
AA			**15MG**	**N08732 002**
AA		SCS PHARMS	**7.5MG**	**N08732 003**
AA			**15MG**	**N08732 002**

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
KAINAIR

AT		PHARMAFAIR	**0.5%**	**N88087 001 JUN 07, 1983**
	@		0.5%	N88087 001 JUN 07, 1983

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD		DANBURY PHARMA	50MG	N80932 001
	@		50MG	N80932 001
BD		LANNETT	50MG	N80016 001
	@		50MG	N80016 001
BD		TABLICAPS	50MG	N80840 001
	@		50MG	N80840 001

PROTIRELIN

INJECTABLE; INJECTION
RELEFACT TRH

AP		FERRING LABS	**0.5MG/ML**	**N18087 001**
		THYREL TRH		
AP		FERRING LABS	**0.5MG/ML**	**N18087 001**

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

	ALLERFED			
AA	PRIVATE FORM	60MG;2.5MG	N88860 001 JAN 31, 1985	
@	PVT FORM	60MG;2.5MG	N88860 001 JAN 31, 1985	

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

	PYRIDOSTIGMINE BROMIDE			
	KALI DUPHAR	30MG	N89572 001 NOV 27, 1990	
@	SOLVAY	30MG	N89572 001 NOV 27, 1990	

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	QUINIDEX			
AB	+ ROBINS AH	300MG	N12796 002	
	QUINIDINE SULFATE			
AB	COPLEY PHARM	300MG	N40045 001 JUN 30, 1994	

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

	ZANTAC 150			
	GLAXO	EQ 150MG BASE	N20095 001 MAR 08, 1994	
	ZANTAC 300			
	+ GLAXO	EQ 300MG BASE	N20095 002 MAR 08, 1994	

GRANULE, EFFERVESCENT; ORAL

	ZANTAC 150			
	+ GLAXO	EQ 150MG BASE/PACKET	N20251 002 MAR 31, 1994	

TABLET, EFFERVESCENT; ORAL

	ZANTAC 150			
	+ GLAXO	EQ 150MG BASE	N20251 001 MAR 31, 1994	

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

	ZEMURON			
	+ ORGANON	10MG/ML	N20214 002 MAR 17, 1994	
	ZEMURON (P/F)			
	+ ORGANON	10MG/ML	N20214 001 MAR 17, 1994	

ROSE BENGAL SODIUM, I-131

INJECTABLE; INJECTION

	ROBENGATOPE			
@	BRACCO DXS	0.5mCi/VIAL	N16224 001	
@		1mCi/VIAL	N16224 002	
@		2mCi/VIAL	N16224 003	
@	SQUIBB	0.5mCi/VIAL	N16224 001	
@		1mCi/VIAL	N16224 002	
@		2mCi/VIAL	N16224 003	

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

	SEREVENT			
	+ GLAXO	EQ 0.021MG BASE/INH	N20236 001 FEB 04, 1994	

SECOBARBITAL SODIUM

CAPSULE; ORAL

	SECOBARBITAL SODIUM			
AA	LANNETT	50MG	N85909 001	
AA		100MG	N85903 001	
@		50MG	N85909 001	
@		100MG	N85903 001	
	SECONAL SODIUM			
AA	LILLY	50MG	N86101 001 OCT 03, 1983	
		50MG	N86101 001 OCT 03, 1983	

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION
SETHOTOPE

@	BRACCO DXS	85-550 uCi/ML	N17047 001
@	SQUIBB	85-550 uCi/ML	N17047 001

SILVER SULFADIAZINE

DRESSING; TOPICAL
SILDIMAC

@	BIOPLASTY	1%	N19608 001 NOV 30, 1989
@	ENQUAY	1%	N19608 001 NOV 30, 1989

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

	BRACCO DXS	250 uCi/VIAL	N13993 001
		1mCi/VIAL	N13993 003
@		2mCi/VIAL	N13993 002
	SQUIBB	250 uCi/VIAL	N13993 001
		1mCi/VIAL	N13993 003
@		2mCi/VIAL	N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
IODOTOPE

	BRACCO DXS	8-100 uCi	N10929 001
		1-50mCi	N10929 003
	SQUIBB	8-100 uCi	N10929 001
		1-50mCi	N10929 003

SOLUTION; ORAL
IODOTOPE

	BRACCO DXS	7-106mCi/BOT	N10929 002
	SQUIBB	7-106mCi/BOT	N10929 002

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

AP	ABBOTT	50MG/VIAL	N18450 001

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

@	ABBOTT	50MG/VIAL	N18450 001

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
PHOSPHOTOPE

@	BRACCO DXS	1-8mCi/VIAL	N10927 001
@	SQUIBB	1-8mCi/VIAL	N10927 001

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE

	BERLEX	120MG	N19865 005 APR 20, 1994

STAVUDINE

CAPSULE; ORAL
ZERIT

@	BRISTOL MYERS SQUIBB	5MG	N20412 001 JUN 24, 1994
		15MG	N20412 002 JUN 24, 1994
		20MG	N20412 003 JUN 24, 1994
		30MG	N20412 004 JUN 24, 1994
+		40MG	N20412 005 JUN 24, 1994

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

AP	PFIZER	**EQ 1GM BASE/2ML**	**N60111 001**
		EQ 1GM BASE/2.5ML	N60111 001

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULFAIR FORTE			
AT	PHARMAFAIR	30%		N88385 001 OCT 13, 1983
	@	30%		N88385 001 OCT 13, 1983
	SULFAIR-15			
AT	PHARMAFAIR	15%		N88186 001 MAY 25, 1983
	@	15%		N88186 001 MAY 25, 1983

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE			
AB	+ EON LABS	500MG		N40091 001 JUL 29, 1994
AB	EON MANUFACTURE LABS	500MG		N40091 001 JUL 29, 1994
AB	+ LILLY	500MG		N04122 002
	@	500MG		N04122 002

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	FUJISAWA	80MG/ML;16MG/ML		N70223 001 DEC 29, 1987
	@	80MG/ML;16MG/ML		N70223 001 DEC 29, 1987

SUSPENSION; ORAL

	BACTRIM			
AB	+ ROCHE	200MG/5ML;40MG/5ML		N17560 001
	@	200MG/5ML;40MG/5ML		N17560 001
	BACTRIM PEDIATRIC			
AB	ROCHE	200MG/5ML;40MG/5ML		N17560 002
AB	+	200MG/5ML;40MG/5ML		N17560 002
	TRIMETH/SULFA			
AB	BARRE	200MG/5ML;40MG/5ML		N72398 001 MAY 23, 1988
	@	200MG/5ML;40MG/5ML		N72398 001 MAY 23, 1988

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	EON LABS	400MG;80MG		N18598 003 MAY 19, 1982
	@	400MG;80MG		N18598 003 MAY 19, 1982
	UROPLUS DS			
AB	SHIONOGI	800MG;160MG		N71816 001 SEP 28, 1987
	@	800MG;160MG		N71816 001 SEP 28, 1987
	UROPLUS SS			
AB	SHIONOGI	400MG;80MG		N71815 001 SEP 28, 1987
	@	400MG;80MG		N71815 001 SEP 28, 1987

SULFASALAZINE

SUSPENSION; ORAL

	AZULFIDINE			
	+ KABI	250MG/5ML		N18605 001
		250MG/5ML		N86983 001
	@ PHARMACIA	250MG/5ML		N18605 001
	+	250MG/5ML		N86983 001

SULFISOXAZOLE

TABLET; ORAL

	SULFISOXAZOLE			
AB	LANNETT	500MG		N80085 001
	@	500MG		N80085 001

TACROLIMUS

CAPSULE; ORAL

	PROGRAF			
	+ FUJISAWA	EQ 1MG BASE		N50708 001 APR 08, 1994
	+	EQ 5MG BASE		N50708 002 APR 08, 1994

INJECTABLE; INJECTION

	PROGRAF			
	+ FUJISAWA	EQ 5MG BASE/ML		N50709 001 APR 08, 1994

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
+ ZENECA — EQ 20MG BASE — N17970 002 MAR 21, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
BS BRACCO DXS — N/A — N17833 001
BS SQUIBB — N/A — N17833 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION
RENOTEC
@ BRACCO DXS — N/A — N17045 001
@ SQUIBB — N/A — N17045 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
MDP-SQUIBB
AP BRACCO DXS — N/A — N18107 001
AP SQUIBB — N/A — N18107 001

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION
OSTEOSCAN-HDP
MALLINCKRODT — N/A — N18321 001
TECHNESCAN HDP
MALLINCKRODT — N/A — N18321 001

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
DUPONT — N/A — N19785 001 DEC 21, 1990
DUPONT MERCK — N/A — N19785 001 DEC 21, 1990

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL
TESULOID
AP SQUIBB — N/A — N16923 001

SOLUTION; INTRAVENOUS, ORAL
TESULOID
AP BRACCO DXS — N/A — N16923 001

TETRACYCLINE

SYRUP; ORAL
ACHROMYCIN V
AB + LEDERLE — EQ 125MG HCL/5ML — N50263 002
SUMYCIN
AB SQUIBB — EQ 125MG HCL/5ML — N60400 001
TETRACYCLINE
AB BARRE — EQ 125MG HCL/5ML — N60633 001
AB MK — EQ 125MG HCL/5ML — N60174 001
TETRACYCLINE HCL
AB PUREPAC — EQ 125MG HCL/5ML — N60291 001
TETRACYN
AB PFIPHARMECS — EQ 125MG HCL/5ML — N60095 001
TETRAMED
AB ZENITH — EQ 125MG HCL/5ML — N61468 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB ICN — 500MG — N60471 002
@ — 500MG — N60471 002

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
+ ON SITE — 12.7MG/FIBER — N50653 001 MAR 25, 1994

SYRUP; ORAL
ACHROMYCIN V
AB + LEDERLE — 125MG/5ML — N50263 002
SUMYCIN
AB SQUIBB — 125MG/5ML — N60400 001
TETRACYCLINE HCL
AB BARRE — 125MG/5ML — N60633 001
AB MK LABS — 125MG/5ML — N60174 001

TETRACYCLINE HYDROCHLORIDE

SYRUP; ORAL

	TETRACYCLINE HCL			
AB	PUREPAC PHARM	125MG/5ML	N60291 001	
	TETRACYN			
AB	PFIPHARMECS	125MG/5ML	N60095 001	
	TETRAMED			
AB	ZENITH LABS	125MG/5ML	N61468 001	

TABLET; ORAL

	PANMYCIN			
AB	UPJOHN	500MG	N61705 002	
	@	250MG	N61705 001	
	@	500MG	N61705 002	
	SUMYCIN			
AB	+ APOTHECON	500MG	N61147 004	
	+	500MG	N61147 004	

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

	SLO-BID			
AB	RHONE POULENC RORER	100MG	N87892 001	JAN 31, 1985
AB		125MG	N89540 001	MAY 10, 1989
AB		200MG	N87893 001	JAN 31, 1985
AB	+	300MG	N87894 001	JAN 31, 1985
	THEOPHYLLINE			
AB	INWOOD LABS	100MG	N40052 001	FEB 14, 1994
AB		125MG	N40052 002	FEB 14, 1994
AB		200MG	N40052 003	FEB 14, 1994
AB		300MG	N40052 004	FEB 14, 1994

ELIXIR; ORAL

	LANOPHYLLIN			
AA	LANNETT	80MG/15ML	N84578 001	
	@	80MG/15ML	N84578 001	
	THEOPHYLLINE			
AA	BARRE	80MG/15ML	N89223 001	MAY 27, 1988

THEOPHYLLINE

ELIXIR; ORAL

	THEOPHYLLINE			
	@ BARRE	80MG/15ML	N89223 001	MAY 27, 1988
	@ CENCI	80MG/15ML	N87679 001	APR 15, 1982
AA	LIFE LABS	80MG/15ML	N87679 001	APR 15, 1982

INJECTABLE; INJECTION

	THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	4MG/ML	N19212 003	NOV 07, 1984
	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	BAXTER	4MG/ML	N18649 007	JUL 26, 1982
	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	4MG/ML	N19211 007	DEC 14, 1984

SYRUP; ORAL

	ACCURBRON			
	MERRELL DOW	150MG/15ML	N88746 001	NOV 22, 1985
	@	150MG/15ML	N88746 001	NOV 22, 1985
	THEOPHYLLINE			
AA	BARRE	80MG/15ML	N86001 001	
	@	80MG/15ML	N86001 001	

THYROGLOBULIN

TABLET; ORAL

	PROLOID		
BP	+ PARKE DAVIS	65MG	N02245 002
		32MG	N02245 005
		100MG	N02245 008
		130MG	N02245 010
		200MG	N02245 007
	@	32MG	N02245 005
	@	65MG	N02245 002
	@	100MG	N02245 008
	@	130MG	N02245 010
	@	200MG	N02245 007
	THYROGLOBULIN		
	+ GLOBAL PHARMS	64.8MG	N80151 001

THYROGLOBULIN

TABLET; ORAL
THYROGLOBULIN

BP	RICHLYN	64.8MG	N80151 001	

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT	STERIS	0.3%	N63176 001 MAY 25, 1994	

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	APOTHECON	EQ 10MG BASE/ML	N64021 001 MAY 31, 1994	
AP		EQ 40MG BASE/ML	N64021 002 MAY 31, 1994	
AP		EQ 40MG BASE/ML	N64026 001 MAY 31, 1994	
	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			> ADD >
	+ ABBOTT	EQ 1.6MG BASE/ML	N63081 006 JUN 02, 1993	> ADD >

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

AB	MYLAN	EQ 600MG BASE	N74473 001 AUG 30, 1994

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE

BP	MYLAN	2MG	N84406 001
	@	2MG	N84406 001

TRIAMCINOLONE ACETONIDE

AEROSOL; TOPICAL
KENALOG

	+ APOTHECON	0.147MG/GM	N12104 001
	+ WESTWOOD SQUIBB	0.147MG/GM	N12104 001

CREAM; TOPICAL
KENALOG

AT	+ APOTHECON	0.025%	N11601 003
AT	+	0.1%	N11601 006
AT	+	0.5%	N83943 001
AT	+ WESTWOOD SQUIBB	0.025%	N11601 003
AT	+	0.1%	N11601 006
AT	+	0.5%	N83943 001

OINTMENT; TOPICAL
KENALOG

AT	+ APOTHECON	0.025%	N11600 003
AT	+	0.1%	N11600 001
AT	+	0.5%	N83944 001
AT	+ WESTWOOD SQUIBB	0.025%	N11600 003
AT	+	0.1%	N11600 001
AT	+	0.5%	N83944 001

TRIAMCINOLONE ACETONIDE

AT	TARO PHARMS	0.025%	N40040 001 SEP 30, 1994
AT		0.1%	N40037 001 SEP 30, 1994

TRIAZOLAM

TABLET; ORAL
HALCION

AB	UPJOHN	0.125MG	N17892 003 APR 26, 1985
AB		0.25MG	N17892 001 NOV 15, 1982

TRIAZOLAM

AB	ALPHAPHARM	0.125MG	N74031 001 MAR 25, 1994
AB		0.25MG	N74031 002 MAR 25, 1994
AB	ROXANE	0.125MG	N74224 001 JUN 01, 1994
AB		0.25MG	N74224 002 JUN 01, 1994

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	ARTANE			
	+ LEDERLE	5MG		N06773 010
		5MG		N12947 001
	@	5MG		N06773 010
	+	5MG		N12947 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION; ORAL

	LANTRISUL			
AB	LANNETT	167MG/5ML;167MG/5ML; 167MG/5ML		N80123 002
	@	167MG/5ML;167MG/5ML; 167MG/5ML		N80123 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	MYDRIAFAIR			
AT	PHARMAFAIR	0.5%		N88274 001 SEP 16, 1983
AT		1%		N88230 001 SEP 16, 1983
	@	0.5%		N88274 001 SEP 16, 1983
	@	1%		N88230 001 SEP 16, 1983
	TROPICAMIDE			
AT	BAUSCH AND LOMB	0.5%		N40067 001 JUL 27, 1994
AT		1%		N40064 001 JUL 27, 1994

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR			
AB	+ KNOLL PHARM	180MG		N19152 002 DEC 15, 1989
	VERAPAMIL HCL			
AB	BAKER NORTON	180MG		N74330 001 JAN 31, 1994

VINBLASTINE SULFATE

INJECTABLE; INJECTION

	VINBLASTINE SULFATE			
AP	BULL	10MG/VIAL		N89565 001 AUG 18, 1987
AP	FAULDING	10MG/VIAL		N89565 001 AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE			
AP	FUJISAWA	1MG/ML		N70411 001 SEP 10, 1986
	@	1MG/ML		N70411 001 SEP 10, 1986
	VINCRISTINE SULFATE PFS			
AP	BULL	1MG/ML		N71484 001 APR 19, 1988
AP	FAULDING	1MG/ML		N71484 001 APR 19, 1988

ACETAMINOPHEN

SUPPOSITORY; RECTAL
INFANTS' FEVERALL
UPSHER SMITH 80MG N18337 004
AUG 26, 1992

TABLET, EXTENDED RELEASE; ORAL
TYLENOL
+ MCNEIL 650MG N19872 001
JUN 08, 1994

BACITRACIN

OINTMENT; TOPICAL
BACITRACIN
COMBE 500 UNITS/GM N62799 001
MAY 14, 1987
@ 500 UNITS/GM N62799 001
MAY 14, 1987

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MYCELEX-7 COMBINATION PACK
MILES 1%,100MG N20389 002
JUN 23, 1994

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
BARRE 12.5MG/5ML N70497 001
APR 25, 1989
@ 12.5MG/5ML N70497 001
APR 25, 1989

IBUPROFEN

TABLET; ORAL
IBUPROFEN
MCNEIL 200MG N73019 001
MAR 30, 1994
PVT FORM 200MG N73691 001
FEB 25, 1994

INSULIN BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN BR
+ LILLY 100 UNITS/ML N19529 001
APR 28, 1986
@ 100 UNITS/ML N19529 001
APR 28, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION
NPH INSULIN
+ NOVO NORDISK 40 UNITS/ML N17929 001
@ 40 UNITS/ML N17929 001

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC
NAPHCON-A
+ ALCON 0.025%;0.3% N20226 001
JUN 08, 1994
OPCON-A
+ BAUSCH AND LOMB 0.027%;0.315% N20065 001
JUN 08, 1994

NAPROXEN SODIUM

TABLET; ORAL
ALEVE
HAMILTON PHARMS EQ 200MG BASE N20204 002
JAN 11, 1994

PERMETHRIN

LOTION; TOPICAL
NIX
+ BURROUGHS WELLCOME 1% N19918 001
MAY 02, 1990
+ WARNER WELLCOME 1% N19918 001
MAY 02, 1990

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
EFIDAC/24			
+ CIBA CONS	240MG	N20021 002	DEC 15, 1992
PSEUDOEPHEDRINE HCL			
ALZA	240MG	N20021 002	DEC 15, 1992
SUDAFED 12 HOUR			
+ BURROUGHS WELLCOME	120MG	N73585 001	OCT 31, 1991
+ WARNER WELLCOME	120MG	N73585 001	OCT 31, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HLTHCARE N940404
JUL 28, 1994

INDIUM IN^{111} CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION
NONE
MALLINCKRODT N/A N19841
SEP 27, 1994

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January-September, 1994]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
8-METHOXSALEN TN= UVADEX	FOR THE PREVENTION OF ACUTE REJECTION OF CARDIAC ALLOGRAFTS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 05/12/94 MA / /
AMINOSALICYLIC ACID TN= PASER GRANULES	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY 37 CLEVELAND LANE PRINCETON NJ 08540 DD 02/19/92 MA 06/30/94
AMINOSIDINE TN= PAROMOMYCIN	TREATMENT OF VISCERAL LEISHMANIASIS (KALA-AZAR).	KANYOK, THOMAS P. PHARM.D. UNIV. OF ILLINOIS AT CHICAGO CHICAGO IL 60612 DD 09/09/94 MA / /
AMIODARONE HCL TN= CORDARONE	FOR THE ACUTE TREATMENT AND PROPHYLAXIS OF LIFE-THREATENING VENTRICULAR TACHYCARDIA OR VENTRICULAR FIBRILLATION.	WYETH-AYERST LABORATORIES P.O. BOX 8299 PHILADELPHIA PA 19101-1245 DD 03/16/94 MA / /
AMMONIUM TETRATHIOMOLYBDATE TN=	TREATMENT OF WILSON'S DISEASE.	BREWER, GEORGE J. M.D. UNIVERSITY OF MICHIGAN MEDICAL SCHOOL ANN ARBOR MI 48109-0618 DD 01/31/94 MA / /
ANTIVENIN, POLYVALENT CROTALID (OVINE) FAB TN= CROTAB	TREATMENT OF ENVENOMATIONS INFLICTED BY NORTH AMERICAN CROTALID SNAKES.	THERAPEUTIC ANTIBODIES INC. 1500 21ST AVENUE SOUTH, SUITE 310 NASHVILLE TN 37212 DD 01/12/94 MA / /
ARGININE BUTYRATE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
AUTOLYMPHOCYTE THERAPY TN=	TREATMENT OF RENAL CELL CARCINOMA.	CELLCOR INCORPORATED 200 WELLS AVENUE NEWTON MA 02159 DD 07/12/94 MA / /
BACLOFEN TN= LIORESAL INTRATHECAL	TREATMENT OF SPASTICITY ASSOCIATED WITH CEREBRAL PALSY.	MEDTRONIC, INCORPORATED 800 53RD AVENUE N.E. MINNEAPOLIS MN 55432 DD 09/26/94 MA / /
BETAINE TN=	TREATMENT OF HOMOCYSTINURIA.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 05/16/94 MA / /
BOVINE IMMUNOGLOBULIN CONCENTRATE, CRYPTOSPORIDIUM PARVUM TN= SPORIDIN-G	TREATMENT AND SYMPTOMATIC RELIEF OF CRYPTOSPORIDIUM PARVUM INFECTION OF THE GASTROINTESTINAL TRACT IN IMMUNOCOMPROMISED PATIENTS.	GALAGEN, INCORPORATED 4001 LEXINGTON AVENUE NORTH ARDEN HILLS MN 55126-2998 DD 03/01/94 MA / /
BUPRENORPHINE HYDROCHLORIDE TN=	TREATMENT OF OPIATE ADDICTION IN OPIATE USERS.	RECKITT & COLMAN PHARMACEUTICALS, INC. 1901 HUGUENOT ROAD RICHMOND VA 23235 DD 06/15/94 MA / /
BUSULFAN TN=	FOR USE AS PREPARATIVE THERAPY FOR MALIGNANCIES TREATED WITH BONE MARROW TRANSPLANTATION.	SPARTA PHARMACEUTICALS, INC. P.O. BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 04/21/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
BUSULFAN TN=	AS PREPARATIVE THERAPY IN THE TREATMENT OF MALIGNANCIES WITH BONE MARROW TRANSPLANTATION.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 07/28/94 MA / /
CCD 1042 TN=	TREATMENT OF INFANTILE SPASMS.	COCENSYS, INC. 213 TECHNOLOGY DRIVE IRVINE CA 92718 DD 05/25/94 MA / /
CHIMERIC (MURINE VARIABLE, HUMAN CONSTANT) MAB TO CD20 TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 06/13/94 MA / /
CHOLINE CHLORIDE TN=	TREATMENT OF CHOLINE DEFICIENCY,SPECIFICALLY THE CHOLINE DEFICIENCY, HEPATIC STEATOSIS, AND CHOLESTASIS, ASSOCIATED WITH LONG-TERM PARENTERAL NUTRITION.	BUCHMAN, ALAN M.D. 6550 FANNIN, SUITE 1122 HOUSTON TX 77030 DD 02/10/94 MA / /
CLADRIBINE TN= LEUSTATIN	TREATMENT OF THE CHRONIC PROGRESSIVE FORM OF MULTIPLE SCLEROSIS.	R.W. JOHNSON RESEARCH INSTITUTE 700 ROUTE 200 SOLUTH, P.O. BOX 670 RARITAN NJ 08869-0670 DD 04/19/94 MA / /
CLONAZEPAM TN= KLONOPIN	TREATMENT OF HYPEREKPLEXIA (STARTLE DISEASE).	HOFFMAN-LA ROCHE, INCORPORATED 340 KINGSLAND STREET NUTLEY NJ 07110-1199 DD 08/04/94 MA / /
CY-1899 TN=	TREATMENT OF CHRONIC ACTIVE HEPATITIS B INFECTION IN HLA-A2 POSITIVE PATIENTS.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 03/16/94 MA / /
CYSTEAMINE TN= CYSTAGON	TREATMENT OF NEPHROPATHIC CYSTINOSIS.	MYLAN LABORATORIES, INC 781 CHESTNUT RIDGE ROAD, PO BOX 4310 MORGANTOWN WV 26504-4310 DD 01/25/91 MA 08/15/94
DEHYDROEPIANDROSTERONE TN=	TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND THE REDUCTION IN THE USE OF STERIODS IN STEROID-DEPENDENT SLE PATIENTS.	GENELABS TECHNOLOGIES, INC. 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 DD 07/13/94 MA / /
DESMOPRESSIN ACETATE TN=	TREATMENT OF MILD HEMOPHILIA A AND VON WILLEBRAND'S DISEASE.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD COLLEGEVILLE PA 19426 DD 01/22/91 MA 03/07/94
ELLIOTT'S B SOLUTION TN=	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIAS AND ACUTE LYMPHOBLASTIC LYMPHOMAS.	ORPHAN MEDICAL 13911 RIDGEDALE DRIVE MINNETONKA MN 55305 DD 08/24/94 MA / /
FGN-1 TN=	FOR THE SUPPRESSION AND CONTROL OF COLONIC ADENOMATOUS POLYPS IN THE INHERITED DISEASE ADENOMATOUS POLYPOSIS COLI.	CELL PATHWAYS, INC. 1700 BROADWAY, SUITE 2000 DENVER CO 80290 DD 02/14/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
GAMMALINOLENIC ACID TN=	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	ZURIER, ROBERT B. M.D. 55 LAKE AVE. UNIV. OF MASS. MED. CTR. WORCESTER MA 01655 DD 07/27/94 MA / /
HEME ARGINATE TN= NORMOSANG	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	LEIRAS, INCORPORATED 1850 CENTENNIAL PARK DRIVE, SUITE 450 RESTON VA 22091 DD 03/01/94 MA / /
I-131 RADIOLABELED B1 MONOCLONAL ANTIBODY TN=	TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMA.	COULTER CORPORATION 11800 S.W. 147 AVENUE, P.O. BOX 169015 MIAMI FL 33116-9015 DD 05/16/94 MA / /
IMIGLUCERASE TN= CEREZYME	FOR REPLACEMENT THERAPY IN PATIENTS WITH TYPES I, II, AND III GAUCHER'S DISEASE.	GENZYME CORPORATION ONE KENDALL SQUARE CAMBRIDGE MA 02139 DD 11/05/91 MA 05/23/94
IN-111 MURINE MAB(2B8-MX-DTPA) & Y-90 MURINE MAB(2B8-MXDTPA) TN=	TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 09/06/94 MA / /
ISOBUTYRAMIDE TN=	TREATMENT OF SICKLE CELL DISEASE AND BETA THALASSEMIA.	VERTEX PHARMACEUTICALS INC. 40 ALLSTON STREET CAMBRIDGE MA 02139-4211 DD 05/25/94 MA / /
L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID TN= PROCYSTEINE	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	FREE RADICAL SCIENCES, INC. 245 FIRST STREET CAMBRIDGE MA 02142 DD 06/14/94 MA / /
L-CYSTEINE TN=	FOR THE PREVENTION AND LESSENING OF PHOTOSENSITIVITY IN ERYTHROPOIETIC PROTOPORPHYRIA.	TYSON AND ASSOCIATES 12832 SOUTH CHADRON AVENUE HAWTHORNE CA 90250 DD 05/16/94 MA / /
LIPOSOME ENCAPSULATED RECOMBINANT INTERLEUKIN-2 TN=	TREATMENT OF CANCERS OF THE KIDNEY AND RENAL PELVIS.	ONCOTHERAPEUTICS, INC. 1002 EASTPARK BOULEVARD CRANBURY NJ 08512 DD 06/20/94 MA / /
MITOGUAZONE TN=	TREATMENT OF DIFFUSE NON-HODGKIN'S LYMPHOMA, INCLUDING AIDS-RELATED DIFFUSE NON-HODGKIN'S LYMPHOMA.	CTRC RESEARCH FOUNDATION 11812 BECKET STREET POTOMAC MD 20854 DD 03/18/94 MA / /
MOÑOCLONAL AB(MURINE) ANTI-IDIOTYPE MELANOMA ASS'TED ANTIGEN TN= MELIMMUNE	TREATMENT OF INVASIVE CUTANEOUS MELANOMA.	IDEC PHARMACEUTICALS CORPORATION 11011 TORREYANA ROAD SAN DIEGO CA 92121 DD 09/19/94 MA / /
N-TRIFLUOROACETYLADRIAMYCIN-14-VALERATE TN=	TREATMENT OF CARCINOMA IN SITU OF THE URINARY BLADDER.	ANTHRA PHARMACEUTICALS, INC. 19 CARSON ROAD PRINCETON NJ 08540 DD 05/23/94 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
NEUROTROPHIN-1 TN=	TREATMENT OF MOTOR NEURON DISEASE/AMYOTROPHIC LATERAL SCLEROSIS.	ERICSSON, ARTHUR DALE, M.D. 6560 FANNIN, SCURLOCK TOWER, SUITE 720 HOUSTON TX 77303 DD 09/13/94 MA / /
OXANDROLONE TN= HEPANDRIN	TREATMENT OF MODERATE/SEVERE ACUTE ALCOHOLIC HEPATITIS IN THE PRESENCE OF MODERATE PROTEIN CALORIE MALNUTRITION.	BIO-TECHNOLOGY GENERAL CORP. 70 WOOD AVENUE SOUTH ISELIN NJ 08830 DD 03/18/94 MA / /
PEGASPARGASE TN= ONCASPAR	TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL).	ENZON, INC. 40 KINGSBRIDGE ROAD PISCATAWAY NJ 08854-3998 DD 10/20/89 MA 02/01/94
PILOCARPINE TN= SALAGEN	TREATMENT OF XEROSTOMIA INDUCED BY RADIATION THERAPY FOR HEAD AND NECK CANCER.	MGI PHARMA, INC. SUITE 300 E, 9900 BREN ROAD EAST MINNEAPOLIS MN 55343-9667 DD 09/24/90 MA 03/22/94
RECOMBINANT HUMAN GELSOLIN TN=	TREATMENT OF THE RESPIRATORY SYMPTOMS OF CYSTIC FIBROSIS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02124 DD 01/12/94 MA / /
RECOMBINANT VACCINIA (HUMAN PAPILLOMAVIRUS) TN= TA-HPV	TREATMENT OF CERVICAL CANCER.	CANTAB PHARMACEUTICALS RESEARCH, LTD. 184 CAMBRIDGE SCIENCE PARK CAMBRIDGE CB4 4GN UK DD 08/24/94 MA / /
REDUCED L-GLUTATHIONE TN= CACHEXON	TREATMENT OF AIDS-ASSOCIATED CACHEXIA.	TELLURIDE PHARMACEUTICAL CORPORATION 146 FLANDERS DRIVE HILLSBOROUGH NJ 08876-4656 DD 02/14/94 MA / /
RICIN (BLOCKED) CONJUGATED MURINE MOAB (CD6) TN=	TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS, ACUTE T-CELL LEUKEMIA-LYMPHOMA, AND RELATED MATURE T-CELL MALIGNANCIES.	IMMUNOGEN, INC. 148 SIDNEY STREET CAMBRIDGE MA 02139-4239 DD 09/06/94 MA / /
RIFAMPIN, ISONIAZID, PYRAZINAMIDE TN= RIFATER	SHORT-COURSE TREATMENT OF TUBERCULOSIS.	MARION MERRELL DOW, INC. P.O. BOX 9627 KANSAS CITY MO 64134-0627 DD 09/12/85 MA 05/31/94
SOMATROPIN TN= GENOTROPIN/GENOTONORM	TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY.	PHARMACIA, INC. P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 09/06/94 MA / /
SOMATROPIN TN= NUTROPIN (EXCLUSIVITY NOT APPLICABLE)	FOR USE IN THE LONG-TERM TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE DUE TO A LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 03/06/87 MA 03/09/94
SULFADIAZINE TN=	FOR USE IN COMBINATION WITH PYRIMETHAMINE FOR THE TREATMENT OF TOXOPLASMA GONDII ENCEPHALITIS IN PATIENTS WITH AND WITHOUT ACQUIRED IMMUNODEFICIENCY SYNDROME.	EON LABS MANUFACTURING, INC. 227-15 NORTH CONDUIT AVENUE LAURELTON NY 11413 DD 03/14/94 MA 07/29/94

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD= Date Designated MA= Marketing Approval
TIZANIDINE HCL TN= ZANAFLEX	TREATMENT OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS AND SPINAL CORD INJURY.	ATHENA NEUROSCIENCES, INC. 800F GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/31/94 MA / /
TREOSULFAN TN= OVASTAT	TREATMENT OF OVARIAN CANCER.	MEDAC GmbH c/o PRINCETON REG. ASSOC. 65 SOUTH MAIN STREET PENNINGTION NJ 08534 DD 05/16/94 MA / /

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTMBER 1994 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ALBUTEROL (METERED DOSE INHALER - *IN VIVO*)	JAN 27, 1994	
FLURBIPROFEN (TABLET)	DEC 24, 1992	FEB 04, 1994
PHENYTOIN (SUSPENSION AND CHEWABLE TABLET)	MAR 04, 1994	
PHENYTOIN SODIUM (CAPSULE, EXTENDED AND PROMPT)	MAR 04, 1994	

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.					
REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.					
ACYCLOVIR TABLET; ORAL	200MG	93 P-0339/ CP1	NOVOPHARM	NEW DOSAGE FORM	APPROVED FEB 08, 1994
ACYCLOVIR SODIUM INJECTABLE; INJECTION	25MG/ML (20ML/VIAL) (40ML/VIAL)	93 P-0469/ CP1	FAULDING	NEW DOSAGE FORM	APPROVED JUN 09, 1994
ESTRADIOL TABLET; ORAL	1.5MG	93 P-0344/ CP1	BRISTOL MYERS SQIBB	NEW STRENGTH	APPROVED JUN 08, 1994
LOPERAMIDE HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	1MG	93 P-0332/ CP1	ELLIS PHARM CONSULTING	NEW DOSAGE FORM	APPROVED FEB 08, 1994
METHYLTESTOSTERONE CAPSULE; ORAL	25MG	93 P-0459/ CP1	ICN	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	15MG 60MG 100MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM	APPROVED JUN 08, 1994
MORPHINE SULFATE CAPSULE, EXTENDED RELEASE; ORAL	90MG	93 P-0446/ CP1	PHARMA CONSULT	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 08, 1994
PREDNISONE TABLET, CHEWABLE; ORAL	1MG 2.5MG 20MG 50MG	93 P-0333/ CP1	DURA	NEW DOSAGE FORM	APPROVED JUN 08, 1994
PSEUDOEPHEDRINE HYDROCHLORIDE; TERFENADINE CAPSULE, EXTENDED RELEASE; ORAL	120MG 60MG	93 P-0367/ CP1	EURAND AMERICA	NEW DOSAGE FORM	APPROVED FEB 08, 1994
ERRATA					
CIMETIDINE TABLET, EFFERVESCENT; ORAL	200MG 300MG 400MG 800MG	93 P-0048/ CP1*	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED SEP 18, 1993

*Not previously published

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 14TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-21 ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22 REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23 INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24 FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M^2 OR 175MG/M^2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS

REFERENCES
NEW INDICATION

I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106 TREATMENT OF ACROMEGALY
I-107 VAGINAL CANDIDIASIS
I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109 TYPHOID FEVER
I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111 TREATMENT OF PAGET'S DISEASE OF BONE
I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN

REFERENCES
PATENT USE CODE

U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY
U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94 TREATMENT OF ADULTS WITH ADVANCED HIV INFECTION WHO ARE INTOLERANT OF APPROVED THERAPIES WITH PROVEN CLINICAL BENEFIT OR WHO HAVE EXPERIENCED SIGNIFICANT CLINICAL OR IMMUNOLOGIC DETERIORATION WHILE RECEIVING THESE THERAPIES OR FOR WHOM SUCH THERAPIES ARE CONTRAINDICATED
U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19872 001	ACETAMINOPHEN; TYLENOL				NDF	JUN 08, 1997
19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 17, 2004	U-93		
		4501893	FEB 26, 2002		NC	MAR 25, 1997
					ODE	JUN 30, 2001
74346 001	AMINOSALICYLIC ACID; PASER					
18700 001	AMRINONE LACTATE; INOCOR	4072746	JUL 31, 1998	U-7	NCE	JUL 31, 1994
20304 001	APROTININ BOVINE; TRASYLOL				ODE	DEC 29, 2000
18831 001	ATRACURIUM BESYLATE; TRACRIUM	4179507	DEC 18, 1996		I-108	JUN 06, 1997
20233 001	BUDESONIDE; RHINOCORT				NCE	FEB 14, 1999
18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008	U-13		
18343 001	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 002	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 003	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 005	CAPTOPRIL; CAPOTEN	5238924	AUG 24, 2010	U-92	I-101	JAN 28, 1997
18343 006	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-101	JAN 28, 1997
					I-95	SEP 23, 1996
19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
					I-109	JUL 21, 1997
19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
					I-109	JUL 21, 1997
19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	I-66	JUL 21, 1997
					I-109	JUL 21, 1997
20392 001	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
					ODE	AUG 15, 2001
20392 002	CYSTEAMINE BITARTRATE; CYSTAGON				NCE	AUG 15, 1999
					ODE	AUG 15, 2001
20355 001	DESMOPRESSIN ACETATE; DESMOPRESSIN ACETATE				NP	MAR 07, 1997
					ODE	MAR 07, 2001
20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5286497	FEB 14, 2011			
20126 001	DOXEPIN HYDROCHLORIDE; ZONALON	4395420	JUL 26, 2000	U-95	NDF	APR 01, 1997
81295 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
18922 004	ETODOLAC; LODINE	4076831	FEB 28, 1997	U-45	NCE	JAN 31, 1996
20363 002	FAMCICLOVIR; FAMVIR				NCE	JUN 29, 1999
20249 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19834 004	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	19304 001	FENOFIBRATE; LIPIDIL	4058552	NOV 15, 1994		NCE	DEC 31, 1998
>ADD>	19960 001	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
>DLT>	~~19960 001~~	~~FLOSEQUINAN; MANOPLAX~~	~~4552884~~	~~NOV 12, 2002~~	~~U-71~~		
>ADD>	19960 002	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
>DLT>	~~19960 002~~	~~FLOSEQUINAN; MANOPLAX~~	~~4552884~~	~~NOV 12, 2002~~	~~U-71~~		
>ADD>	19960 003	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
>DLT>	~~19960 003~~	~~FLOSEQUINAN; MANOPLAX~~	~~4552884~~	~~NOV 12, 2002~~	~~U-71~~		
>ADD>	19960 004	FLOSEQUINAN; MANOPLAX	4552884	DEC 31, 2006	U-71		
>DLT>	~~19960 004~~	~~FLOSEQUINAN; MANOPLAX~~	~~4552884~~	~~NOV 12, 2002~~	~~U-71~~		
	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000		I-100	DEC 30, 1996
	20322 001	FLUCONAZOLE; DIFLUCAN	4552884	NOV 12, 2002		I-100	DEC 30, 1996
			4302460	NOV 24, 1998		NCE	JAN 29, 1995
						NS	JUN 30, 1997
						I-107	JUN 30, 1997
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4018895	APR 19, 1994	U-12	I-102	FEB 28, 1997
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001		I-102	FEB 28, 1997
	20235 001	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 002	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
	20235 003	GABAPENTIN; NEURONTIN	4894476	JAN 16, 2007			
>ADD>	20123 001	GADODIAMIDE; OMNISCAN	4687659	JAN 08, 2007	U-76	NCE	JAN 08, 1998
>DLT>	~~20123 001~~	~~GADODIAMIDE; OMNISCAN~~	~~4687659~~	~~AUG 18, 2004~~	~~U-76~~	~~NCE~~	~~JAN 08, 1998~~
	20329 001	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	20329 002	GLIPIZIDE; GLUCOTROL XL				NDF	APR 26, 1997
	19778 003	HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3	NS	NOV 18, 1996
	19888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-12.5	4472380	SEP 18, 2001			
			4374829	DEC 30, 2001	U-3		
	19888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC 20-25	4374829	DEC 30, 2001	U-3		
	19888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5	4472380	SEP 18, 2001		NS	NOV 18, 1996
			4374829	DEC 30, 2001	U-3		
>ADD>	19771 001	IBUPROFEN; ADVIL COLD AND SINUS	4552899	NOV 12, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20367 001	IMIGLUCERASE; CEREZYME				NCE	MAY 23, 1999
						ODE	MAY 23, 2001
	20314 001	INDIUM IN-111 PENTETREOTIDE KIT; OCTREOSCAN				NCE	JUN 02, 1999
	20084 001	IOBENGUANE SULFATE I 131; IOBENGUANE SULFATE I 131	4584187	APR 22, 2003		NCE	MAR 25, 1999
	50705 001	ISONIAZID; RIFATER				ODE	MAY 31, 2001
	20336 001	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
			4950486	AUG 21, 2007		NDF	JUN 01, 1997
			4946687	AUG 07, 2007		NCE	DEC 20, 1995
			4816263	MAR 28, 2006	U-3		
			4783337	SEP 16, 2003	U-3		
			4466972	AUG 21, 2003	U-3		
	20336 002	ISRADIPINE; DYNACIRC CR	5030456	JUL 09, 2008			
			4950486	AUG 21, 2007		NDF	JUN 01, 1997
			4946687	AUG 07, 2007		NCE	DEC 20, 1995
			4816263	MAR 28, 2006	U-3		
			4783337	SEP 16, 2003	U-3		
			4466972	AUG 21, 2003	U-3		
	20083 001	ITRACONAZOLE; SPORANOX				I-104	MAR 29, 1997
>ADD>	18754 001	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
>ADD>	18754 002	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
>ADD>	18754 003	KETOPROFEN; ORUDIS				I-112	JAN 06, 1997
	19816 001	KETOPROFEN; ORUVAIL				NDF	SEP 24, 1996
	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	JAN 18, 2000		NCE	NOV 10, 1998
	19558 006	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 2000	U-77	NCE	APR 12, 1998
>DLT>	~~19658 001~~	~~LORATADINE; CLARITIN~~	~~4282233~~	~~AUG 04, 1998~~	~~U-77~~	~~NCE~~	~~APR 12, 1998~~
	20264 001	MEGESTROL ACETATE; MEGACE				NDF	SEP 10, 1997
	20343 001	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	20343 002	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	20343 003	MILRINONE LACTATE; PRIMACOR IN DEXTROSE 5%	4313951	FEB 02, 2001			
	20065 001	NAPHAZOLINE HYDROCHLORIDE; OPCON-A				NC	JUN 08, 1997
	20226 001	NAPHAZOLINE HYDROCHLORIDE; NAPHCON-A				NC	JUN 08, 1997
>ADD>	20204 002	NAPROXEN SODIUM; ALEVE				NS	JAN 11, 1997
>ADD>	19660 001	NEDOCROMIL SODIUM; TILADE	4474787	OCT 02, 2006		NCE	DEC 30, 1997
>DLT>	~~19660 001~~	~~NEDOCROMIL SODIUM; TILADE~~	~~4474787~~	~~OCT 02, 2001~~		~~NCE~~	~~DEC 30, 1997~~

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20165 001	NICOTINE; NICODERM	5344656	APR 02, 2008			
>ADD>	20165 002	NICOTINE; NICODERM	5344656	APR 02, 2008			
>ADD>	20165 003	NICOTINE; NICODERM	5344656	APR 02, 2008			
	19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 004	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
	19667 005	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2002		I-106	MAY 03, 1997
>ADD>	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN				I-110	SEP 26, 1997
>ADD>	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN				I-110	SEP 26, 1997
	20262 001	PACLITAXEL; TAXOL				I-105	APR 13, 1997
						D-24	JUN 22, 1997
	20036 001	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
>ADD>						I-111	SEP 21, 1997
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
>ADD>						I-111	SEP 21, 1997
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004		D-22	APR 15, 1997
>ADD>						I-111	SEP 21, 1997
>ADD>	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
>ADD>	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
>ADD>	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
>ADD>	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
>ADD>	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	NCE	DEC 29, 1997
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	APR 02, 2002		NCE	DEC 30, 1998
	20237 001	PILOCARPINE HYDROCHLORIDE; SALAGEN				ODE	MAR 22, 2001
						NDF	MAR 22, 1997
>ADD>	19898 002	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004		NCE	OCT 31, 1996
>DLT>	~~19898 002~~	~~PRAVASTATIN SODIUM; PRAVACHOL~~	~~4346227~~	~~AUG 24, 1999~~		~~NCE~~	~~OCT 31, 1996~~
>ADD>	19898 003	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004		NCE	OCT 31, 1996
>DLT>	~~19898 003~~	~~PRAVASTATIN SODIUM; PRAVACHOL~~	~~4346227~~	~~AUG 24, 1999~~		~~NCE~~	~~OCT 31, 1996~~
>ADD>	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	JAN 09, 2004		NCE	OCT 31, 1996
>DLT>	~~19898 004~~	~~PRAVASTATIN SODIUM; PRAVACHOL~~	~~4346227~~	~~AUG 24, 1999~~		~~NCE~~	~~OCT 31, 1996~~
	20279 001	PREDNICARBATE; DERMATOP				NDF	OCT 29, 1996
	19627 001	PROPOFOL; DIPRIVAN				I-99	OCT 26, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20021 002	PSEUDOEPHEDRINE HYDROCHLORIDE; EFIDAC/24	4801461	MAY 05, 2004			
		4576604	MAR 18, 2003			
18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4128658	DEC 05, 1995		D-21	FEB 28, 1997
18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4128658	DEC 05, 1995		D-21	FEB 28, 1997
19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4521431	JUN 04, 2002		D-21	FEB 28, 1997
20095 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20095 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	5028432	JUL 02, 2008			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20251 002	RANITIDINE HYDROCHLORIDE; ZANTAC 150	5102665	APR 07, 2009			
		4521431	JUN 04, 2002		I-75	MAY 19, 1995
		4128658	DEC 05, 1995		D-21	FEB 28, 1997
20214 001	ROCURONIUM BROMIDE; ZEMURON (P/F)	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20214 002	ROCURONIUM BROMIDE; ZEMURON	4894369	JAN 16, 2007		NCE	MAR 17, 1999
20236 001	SALMETEROL XINAFOATE; SEREVENT	4992474	FEB 12, 2008		NCE	FEB 04, 1999
19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1996
19640 001	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19640 004	SOMATROPIN, BIOSYNTHETIC; HUMATROPE				D-23	APR 15, 1997
19865 005	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	OCT 30, 1997
					ODE	OCT 30, 1999
20412 001	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 002	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 003	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 004	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
20412 005	STAVUDINE; ZERIT	4978655	DEC 18, 2007	U-94	NCE	JUN 24, 1999
40091 001	SULFADIAZINE; SULFADIAZINE				ODE	JUL 29, 2001
17376 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997		I-103	JAN 07, 1997
17376 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997		I-103	JAN 07, 1997

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	17377 001	SULFAMETHOXAZOLE; BACTRIM				I-103	JAN 07, 1997
	17377 002	SULFAMETHOXAZOLE; BACTRIM DS				I-103	JAN 07, 1997
	17560 002	SULFAMETHOXAZOLE; BACTRIM PEDIATRIC				I-103	JAN 07, 1997
	17598 001	SULFAMETHOXAZOLE; SEPTRA				I-103	JAN 07, 1997
	17598 002	SULFAMETHOXAZOLE; SEPTRA GRAPE				I-103	JAN 07, 1997
>ADD>	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 29, 2006	U-72		
>DLT>	~~20080 001~~	~~SUMATRIPTAN SUCCINATE; IMITREX~~	~~4816470~~	~~MAR 28, 2006~~	~~U-72~~		
	17970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
	19762 001	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
			4725439	FEB 16, 2005			
			4704282	NOV 03, 2004		NDF	OCT 12, 1996
	19762 002	TESTOSTERONE; TESTODERM	4867982	FEB 16, 2005			
			4725439	FEB 16, 2005			
			4704282	NOV 03, 2004		NDF	OCT 12, 1996
	20330 001	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
			4195085	MAR 25, 1997		NP	NOV 04, 1996
	20330 002	TIMOLOL MALEATE; TIMOPTIC-XE	4861760	AUG 29, 2006			
			4195085	MAR 25, 1997		NP	NOV 04, 1996
	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4694007	SEP 15, 2004	U-91	ODE	DEC 17, 2000
>ADD>	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2005	U-74	NCE	DEC 16, 1997
>DLT>	~~19908 001~~	~~ZOLPIDEM TARTRATE; AMBIEN~~	~~4382938~~	~~MAY 05, 2000~~	~~U-74~~	~~NCE~~	~~DEC 16, 1997~~
>ADD>	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2005	U-74	NCE	DEC 16, 1997
>DLT>	~~19908 002~~	~~ZOLPIDEM TARTRATE; AMBIEN~~	~~4382938~~	~~MAY 05, 2000~~	~~U-74~~	~~NCE~~	~~DEC 16, 1997~~

New 15th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

15TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7542

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $64.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/94)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 512-1800.